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ABSTRACT 
 
Bacteria are responsible for up to 70% of all ocular infections including 
conjunctivitis, keratitis and endophthalmitis.  If left untreated, a reduction of visual 
acuity, and in severe cases, sight loss, is possible.  Treatment usually consists of a 
topically applied antibacterial preparation for patients with superficial infections.  With 
intraocular infections, topical administration is augmented with systemic treatment or 
local instillation.  While several types of drugs are available for ocular therapy, the 
fluoroquinolone class of antimicrobials is especially effective.  This is due in part to their 
broad-spectrum of activity and low toxicity.  However, as with any globally prescribed 
antimicrobial agent, bacterial resistance is an issue.  Over the past 10 years there has been 
a decline in the effectiveness of older fluoroquinolones (ciprofloxacin and ofloxacin) in 
treating Gram-positive and, to a lesser extent, certain Gram-negative infections.  In 
response to the declining activity of ciprofloxacin and ofloxacin, newer fluoroquinolones 
have been developed such as levofloxacin (L-isomer of ofloxacin), and more recently, 
gatifloxacin and moxifloxacin.   
In order to ensure the most potent drugs are being used to treat the most serious 
types of infection, studies need to be done to assess the activity of the current 
antimicrobial arsenal against pertinent infecting organisms.  Three different types of 
experiments can be done to achieve this.  In vitro potency can be tested two ways.  The 
first is minimum inhibitory concentration (MIC).  This test defines the concentration of 
antimicrobial drug that prevents growth of bacteria when tested against an inoculum of 
approximately 105 colony forming units (CFU)/ml.  The second is the mutant prevention 
concentration (MPC), which is the amount of drug needed to inhibit a first step resistant 
mutant.  This is a relatively new approach to measuring fluoroquinolone potency; like 
MIC it is not a measure of kill.  A separate set of experiments are needed to assess in 
vitro killing.  Kill curves measure the ability of an antimicrobial agent to reduce/kill a 
bacterial population over a period of 24 hours.   
Because bacterial loads can vary greatly in in vivo infections, kill curves were 
conducted on a series of four inoculum sizes ranging from 106 to 109 cfu/ml.  Some of the 
most common ocular pathogens are Streptococcus pneumoniae, Staphylococcus aureus, 
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Haemophilus influenzae and Pseudomonas aeruginosa.  Mycobacterium fortuitum and 
Mycobacterium chelonae, while much less commonly associated with ocular disease, are 
capable of causing vision-threatening infections.  As a result, the above six organisms 
were used to test the in vitro potency of ciprofloxacin, ofloxacin, levofloxacin, 
moxifloxacin and gatifloxacin.   
Both MIC and MPC testing found both gatifloxacin and moxifloxacin to be 4-8-
fold more potent in vitro against the Gram-positive organisms than the older 
fluoroquinolones with an average potency rank order of moxifloxacin = gatifloxacin > 
levofloxacin > ofloxacin = ciprofloxacin.  The Gram-negative results, however, revealed 
that the older fluoroquinolones are still the most potent of the fluoroquinolones tested 
with an average potency rank order of ciprofloxacin > ofloxacin = levofloxacin > 
gatifloxacin = moxifloxacin.   
Kill curve results showed a significant difference in the rate of killing between the 
MIC and MPC drug concentrations.  At the MIC drug concentration there was generally 
only a noticeable reduction in viable cells following 24 hours of drug exposure and in 
many cases this was followed by a period of bacterial re-growth.  At the MPC drug 
concentration, a significant bacterial count reduction was often observed as early as 4 to 6 
hours for both S. pneumoniae and H. influenzae.  Surprisingly, there was little difference 
between the five fluoroquinolones in their rates of and amount of bacterial reduction. 
Because of high in vitro resistance rates in drugs like penicillin, the 
fluoroquinolones are an important broad-spectrum alternative.  Consequently, it is 
imperative that measures are taken to maintain the efficacy of this class.  One approach  
is to ensure that the most potent drug is being used to eradicate possible resistant sub-
populations present in in vivo infections.  The data from these experiments suggest that 
the new fluoroquinolones gatifloxacin and moxifloxacin are much more potent (in vitro) 
than older fluoroquinolones against Gram-positive bacteria.  With Gram-negative 
pathogens, however, ciprofloxacin remains the most potent agent in vitro.             
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1.0     Introduction 
 1.1     General Overview 
 Ocular infections account for 1-4% of all patient-physician visits and result 
primarily from bacterial or viral pathogens (1).  Typically the causative bacterial 
organisms are Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas 
aeruginosa and Haemophilus influenzae.  While there are a wide variety of other 
organisms that also have the potential to cause infection, the genus and species listed 
above are the most common.  The ocular structures most often involved in an infection 
are the conjunctiva, cornea and aqueous/vitreous humor.           
 1.2     Ocular Physiology 
  1.2.1     Conjunctiva 
 The conjunctiva consists of a mucous membrane that lines the inner portions of 
the eyelids and is reflected onto the globe covering the sclera to the limbus.  It is made 
up of three sections:  the palpebral/tarsal conjunctiva, fornix conjunctiva and the bulbar 
conjunctiva (Fig 1.1)(2).       
 The conjunctiva possesses several mechanisms of defense which can be 
categorized as non-immune and immune.  The non-immune mechanisms are barriers 
which help protect the underlying conjunctival tissues from infection.  These include 
the intact mucous membrane surface, rapid epithelial cell turnover, cool temperature 
due to tear evaporation, the mechanical action of the eyelids and the flushing action of 
the tears and lacrimal system  (2).  The normal flora (Staphylococcus epidermidis, S. 
aureus and Corynebacterium species) are typically non-virulent organisms which 
colonize the ocular surfaces and metabolize the nutrients available in the ocular 
environment.  This makes it difficult for more virulent organisms (which may be of the 
same species as the normal flora) to proliferate in the same area causing an infection.  In 
addition, the  tear film constituents lactoferrin, β-lysine and lysozyme have antibacterial 
actions which complement the anatomical barriers (3).  Often during an infection, a dry 
eye state occurs due to a diminished tear film.  To compensate for this, additional 
antibacterial proteins may leak out from inflamed blood vessels (4).   
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Figure 1.1:  Anatomic division of the conjunctiva (5).   
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 The conjunctiva is a highly vascularized structure.  As a result, all cellular 
components of the immune system are present in the conjunctival substantia propria 
except basophils and eosinophils (2).  
 While the tear film is technically a separate entity, its structure and function is 
so closely linked to that of the conjunctiva that it will be discussed in the same section. 
The tear film is a three layered structure consisting of an outer lipid layer, a middle 
aqueous layer which is approximately 7-10 mm thick and a mucous layer (6).  Each of 
the three layers is secreted by different tissues.  The outer lipid layer is secreted 
primarily by meibomian glands which are located within the lower and upper eyelids.  
The constituents of this layer include wax monoesters, sterol esters, hydrocarbons, 
triglycerides, diglycerides, free sterols, free fatty acids and polar lipids (7).  The middle 
aqueous layer is secreted by the main lacrimal gland, accessory lacrimal gland and both 
the corneal and conjunctival epithelial cells.  This layer is made up of antibacterial 
proteins, immunoglobins, growth factors, lysozyme, lactoferrin, secretory IgA, 
electrolytes and water (8).  The inner mucous layer is produced by conjunctival goblet 
cells as well as stratified squamous cell from the conjunctiva and cornea (Fig 1.2)(9).  
 The tear film is essential for the health, maintenance, and protection of the 
ocular surface.  It contributes to the smooth optical properties of the corneal surface.  It 
is a primary source of oxygen to the cornea.  It acts as a lubricant between the eye lids 
and ocular surface.  Also, the movement of tears across the ocular surface and their 
drainage into the nasolacrimal duct help remove foreign bodies, debris and exfoliated 
cells.  Finally, as mentioned above, the tear film contains antibacterial proteins which 
help protect the conjunctiva and cornea (9)                   
  1.2.2     Cornea 
 The cornea is a unique assembly of structures that when combined produce an 
almost perfectly transparent, avascular optical tissue that serves as a physical barrier 
between the environment and the inside of the eye.  It is also a major refractive structure 
that focuses light onto the retina (9).  The cornea is composed of six layers which vary 
greatly in thickness.  The outermost layer is the epithelium.  It is 5-7 cells thick and is 
made up of three types of cells:  basal cells, wing cells and superficial cells.  The basal 
cells form a single cell layer which is attached to the basement membrane via   
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Figure 1.2:  Schematic showing the glands and epithelia of the eye and ocular surface 
that contribute to the tear film.  (9) 
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hemidesmosomes.  It is at this layer where mitosis occurs.  As cell division occurs the 
cells begin to differentiate, forming the wing cells which are one to three layers thick.  
These cells represent an intermediate state of differentiation.  The superficial cells are 
terminally differentiated and make up the outermost layer which is three to four cells 
thick.  At this point the cells degenerate and are sloughed off from the corneal surface.  
The epithelium has a turnover rate of about seven days (10).  As a result, a corneal 
injury that damages only the epithelium will heal without a scar. 
 The second layer is only 40-60 μm thick and is made up of type IV collagen, 
type VII collagen, laminin, heparin sulfate and proteoglycan (11).  The third layer is the 
Bowman’s layer.  It is 12 μm thick and is made up of randomly arranged type I collagen 
fibers.  It is thought that this layer acts as a stabilizing element in the cornea (12).   
 The stroma is the fourth and thickest layer.  Making up 90% of the thickness of 
the cornea, it is 0.65 mm thick at the peripheral portions and 0.52 mm at the central 
portion (13).  The Descemet’s membrane is the fifth layer.  Its thickness is 10-15 μm 
early on in life, and increases in thickness with age.  This membrane in secreted by the 
endothelial cells and is made up type IV collagen, laminin and fibronectin.  The 
fibronectin is responsible for the adhesion of this membrane to the endothelial cells 
(14). 
 The endothial cells make up the final and innermost layer of the cornea (Fig 1.3) 
(9).  It is a single layer of hexagonal cells (4-6 μm thick) which are incapable of 
replicating.  With age, the number of endothial cells decreases.  As a result, the 
neighboring cells enlarge to fill the gap (15).  The junctions between cells are such that 
a leaky barrier is formed between the aqueous humor and the stroma.  This allows the 
entry of nutrients into the avascular stroma.  There is also an endothelial system of 
metabolic pumps, ion transporters and channels which interact to osmotically remove 
water from the stroma to ensure corneal transparency (16).                 
  1.2.3     Aqueous Humor 
 The aqueous humor is a liquid body located immediately behind the cornea, just 
in front of the lens.  It was previously thought that this was a stagnant fluid, but it has 
since been shown to be continuously formed and drained (17).  Three physiological 
processes are involved in the formation and chemical composition of the  
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Figure 1.3:  Histological section of a normal human cornea stained with Periodic Acid 
Schiff reveals the outer epithelium (EP), basement membrane (BM), Bowman’s layer 
(BL), stroma (ST), Descemet’s membrane (DM), and endothelial monolayer (EN). (9) 
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aqueous humor: diffusion, ultrafiltration and active secretion (5).  Diffusion involves 
the passive flow of solutes across a cell membrane down a concentration gradient.  
Ultrafiltration refers to the bulk flow of blood plasma from the ciliary capillary into the 
ciliary stroma.  This process can be aided by the utilization of the hydrostatic driving 
force (6).  Active secretion involves the movement of a solute across a membrane 
against the concentration gradient, at the cost of cellular ATP.   
 The first two processes are responsible for the formation of the reservoir of 
plasma ultrafiltrate in the stroma.  By active secretion, the plasma ultrafiltrate is then 
pumped into the posterior chamber of the aqueous humor.  This active secretion process 
accounts for the formation of  80-90% of the total aqueous humor (18).  In a healthy 
human eye the rate of aqueous humor formation is approximately 2.5 μl x min-1 (19). 
  1.2.4 Vitreous Humor 
 The vitreous humor is the largest structure in the eye, making up 80-90% of its 
total volume (9).  Physically, the vitreous is located behind the lens and extends all the 
way back to the retina (Fig 1.4) (20).  Water makes up 99% of the vitreous’ 
composition.  The rest is made up of solids.  The vitreous acts as a gel to surround the 
large amount of water.  The gel portion consists of long, thick, non-branching, collagen 
fibrils suspended in a network of hyaluronic acid which stabilizes the gel structure and 
the conformation of the collagen fibrils (21). 
The gel structure acts as a barrier against the movement of solutes.  Substances 
may, however, travel in and out of the vitreous via diffusion and bulk flow.  Bulk flow 
influences the movement of high-molecular-weight substances only, and is facilitated 
by the flow of liquid from the retrozonular space (anterior) to the retina (posterior) (22).  
Movement across the blood-retinal barrier is restricted to low-molecular-weight 
substances and occurs via diffusion; similar to that of the blood-brain barrier  (23).
      
 8
 
 
Fig 1.4:  A cross-sectional view of the eye.  (20) 
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 1.3     Bacterial Ocular Infections 
  1.3.1     Conjunctivitis (Pink-eye) 
 The conjunctival resident bacteria, or normal flora, tends to fluctuate with the 
age and physical state of the host, as well as environmental factors (2).  Typically adults 
harbor a greater number of organisms than do children.  Children are colonized with 
higher numbers of Streptococcus species while adults have higher numbers of 
anaerobes such as Propionibacterium species (24).  Also, long-term contact lens 
wearers have higher number of bacterial species than do short-term and non-contact 
lens wearers (25).  While the presence of normal flora acts as a natural defense 
mechanism by out-competing pathogenic bacteria, normal flora may cause infection in 
immunocomprimised or debilitated patients.   
 Realistically any microbial organism can lead to conjunctivitis.  However, the 
most common bacterial pathogens are S. aureus, H. influenzae and S. pneumoniae (2) 
(Table 1.1).  The method of transmission can be any of the following:  hand to eye, 
person to person, contaminated instruments or surfaces and inadvertent sexual contact.  
Symptoms usually include chemosis, hyperemia and discharge/exudates.  The severity 
of the symptoms depends on the infectious agent present, and the type of immune 
response elicited (2).  For example, when exudate is present, it may be serous, mucoid, 
purulent or hemorrhagic (26).        
 Conjunctival membranes or pseudomembranes may be present as a result of 
infection.  Both consist of fibrin and cellular debris.  The true membranes actually 
attach to the conjunctival epithelium.  As a result, when removed, the membranes leave 
a raw and bleeding surface.  In contrast, the pseudomembranes are not attached to the 
conjunctival surface, so when removed there is no trauma (26).  As with the type of 
exudates present, the type of membrane can help establish a differential diagnosis.              
 Similar to other infections, the symptoms are created mostly by the immune 
response.  This consists primarily of an infiltration of lymphocytes, neutrophils, mast 
cells and plasma cells which coincides with an increase in the ocular vascular 
permeability (27).     
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Type of Infection Organism Prevelance (%) Reference
Conjunctivitis Gram - positive 75.0 Everett et al . 1995
Coagulase Negative Staphylococcus 39.0
S. aureus 25.0
Gram - negative 25.0
H. influenzae 9.0
Enteric Gram - negatives 5.4
Pediatric Conjunctivitis H. influenzae 20 to 75 Block et a l. 2000
S. pneumoniae 12 to 20
Keratitis Gram - positive 48.0 Alexandrakis et al.  2000
S. aureus 19.4
Streptococus  species 6.7
Diptheroids 2.3
S. epidermidis 1.3
Gram - negative 50.0
P. aeruginosa 25.7
Serratia marcescens 7.6
Proteus  species 3.7
Haemophilus  species 2.5
Endophthalmitis Gram - positive 37.6 Anand et al . 2000
S. epidermidis 12.9
S. aureus 7.6
P. acnes 5.9
Streptococcus  species 4.1
Gram - negative 41.7
P. aeruginosa 17.1
Other Gram  - nagative bacilli 10.6
Other non-fementing bacilli 8.8  
Table 1.1:  Prevalence rates of bacteria most commonly associated with conjunctivitis, keratitis and endophthalmitis.   
10 
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 While mild conjunctivitis is often self-limiting, treatment is sometimes given to 
reduce patient anxiety, prevent spread to the other eye and shorten the duration of the 
disease (28).  Treatment consists of a topical broad spectrum antibiotic such as an 
aminoglycoside or a fluoroquinolone given four times daily for five to seven days.  
Moderate conjunctivitis requires more frequent doses such as six to eight times daily for  
seven to ten days.  Treatment for severe acute conjunctivitis will last for seven to 
fourteen days and may include concurrent systemic treatment if preseptal cellulitis or 
otitis media are involved.  This is especially important for children if H. influenzae is 
the causative organism (2).  
  1.3.2     Keratitis 
 Because of its high incidence and potential complications, bacterial keratitis is 
one of the most visually threatening ocular infectious diseases.  The avascular cornea is 
particularly susceptible to bacterial infection, and many patients have a poor clinical 
outcome it aggressive therapy is not initiated promptly (29).  Organisms such as S. 
aureus and P. aeruginosa have been known to create corneal perforations in less than 
24 hours (30).   
 Normal flora for the cornea consists primarily of S. epidermidis and diptheroids, 
but also S. aureus, S. pneumoniae, P. aeruginosa and Neisseria meningitidis (31) (Table 
1.1).  The primary pathogens are S. aureus, S. pneumoniae and P. aeruginosa.   
 Corneal infections result mostly from a failure of one of the host defense 
mechanisms.  Most bacteria cannot penetrate an intact corneal epithelium, with the 
exception of Neisseria gonorrheae and H. influenzae, because it is protected by eyelids 
and tear film (15).  Consequently, it takes a condition such as dry eye, or trauma to the 
cornea to facilitate the development of a bacterial infection.  The advent of contact 
lenses has led to a significant (15-20-fold) increase in the incidence  of ulcerative 
conjunctivitis (32).  This is because the cornea epithelial cells receive micro-abrasions 
every time a contact lens is inserted or removed.  This creates additional opportunities 
for pathogens, especially P. aeruginosa, to invade (33).  Additional  risk factors 
include:  poor personal hygiene, diabetes mellitus, ocular steroid use, recent ocular 
surgery and use of contaminated ophthalmic solutions (34).    
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 Symptoms of keratitis often include a rapid onset of pain, conjunctival injection, 
decreased vision, photophobia and white cell infiltrate (20).  Other conditions such as 
uveitis, edema and opacification may also appear.  Corneal infections result in the 
release of prostaglandins and other chemical mediators.  A combination of 
prostaglandin-mediated miosis, breakdown of the blood-aqueous barrier and 
vasodilation contribute to the development of anterior uveitis (35).  Edema may also be 
present.  If the damage remains at the epithelial level, the edema may be quite localized.  
If the damage extends down to the endothelial layer, however, the edema may be quite 
diffuse.  Lastly, inflammatory cells may enter the cornea via limbal vasculature or tear 
film in response to antigens, toxins or other irritants.  This presents as cloudy corneal 
infiltrates (36). 
 Treatment of infectious keratitis must occur swiftly upon diagnosis and the 
patient’s progress must be closely monitored.  While specimens are not usually 
collected in cases of conjunctivitis, it is important to do so for keratitis.  While waiting 
for the lab results, treatment via combination therapy or a monotherapeutic agent needs 
to occur.  Combination therapy refers to the use of two antimicrobial agents to get better 
Gram-positive and Gram-negative coverage.  This usually involves combining an 
aminoglycoside, such as tobramycin, and a cephalosporin like cefazolin.  Monotherapy 
refers to the use of a single antimicrobial agent which has sufficient spectrum of activity 
to be used alone.  An example of a monotherapeutic agent would be any of the 
ophthalmic fluoroquinolones. 
 For the first 24 hours of treatment, installation of the antibiotic needs to occur 
hourly.  If the response is favorable then the frequency can be reduced to 2-hourly.  If 
progress is not being made (ex. ulceration progressing), the physician can refer to the 
lab results to determine what antibiotic would most likely be effective based on in vitro 
susceptibility results (15).        
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  1.3.3     Endophthalmitis 
 Bacterial endophthalmitis can develop a few different ways.  It is most often a 
postoperative infection but it can also arise from a corneal ulcer which perforates the 
cornea, or a penetrating trauma.  The source of infection is usually the patient’s own 
eyelid, conjunctival or lacrimal flora.  It may sometimes come from contaminated 
surgical solutions, instruments or environmental flora (15).  Common pathogens include 
S. epidermidis, S. aureus, Pseudomonas species and Proteus species (Table 1.1). 
  Clinical features of mild endophthalmitis include slight pain, preservation of 
some red reflex (the natural color reflected off of a healthy retina), and possibly a small 
hypopyon (presence of leucocytes).  Moderate endophthalmitis results in fibrinous 
exudates in the vitreous, small hypopyon, vitritis and an absence of red reflex.  Severe 
endophthalmitis presents with pain, significant visual loss, lid edema, chemosis, 
conjunctival injection, purulent discharge, corneal infiltrates and large hypopyon (15). 
 Prior to initiating treatment, vitreous and aqueous specimens should be collected 
and sent to the lab.  This should consist of a 100 μl aqueous aspirate and a 100-300 μl 
aspirate from the vitreous.  Treatments vary depending on the severity of the infection.  
One option is to use intravitreal injections.  Like other types of ocular infections, this is 
done using a fluoroquinolone or a combination of agents.  This is done once daily for 
five to seven days.  One problem with this type of therapy is that some drugs show 
retinotoxicity, which can result in additional sight loss.  Aminoglycosides are 
particularly noted for this (15).  Despite this, intravitreal injections are the fastest way to 
administer drugs to the vitreous.   Another method of treatment is topical therapy.  This 
has limited effectiveness because unless there is a damaged corneal epithelium, as with 
infectious keratitis, the topical drugs either take a long time to reach bactericidal 
concentrations in the vitreous or they do not reach bactericidal concentrations at all.  
The last option is systemic treatment.  This usually is not recommended due to poor 
ocular penetration.  Ocular drug concentrations only reach approximately 10-20% of 
serum concentrations (37).  Despite aggressive therapy 55% of eyes achieve a final 
visual acuity of 6/60 or less (15).  In severe cases where visual acuity is reduced to light 
perception, a vitrectomy will be performed.                   
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 1.4     Antimicrobial Therapy for Bacterial Ocular Infections 
  1.4.1     Topical/Systemic 
 Typically for most ocular infections, with the exception of endophthalmitis, the 
two treatment options are either topical or systemic antimicrobial therapy.  As 
mentioned above, systemic treatment alone is not recommended because of the poor 
ocular penetration.  The poor penetration has two consequences.  First, bactericidal 
concentrations at the site of infection are not achieved which may result in therapeutic 
failure.  Second, exposing bacteria to non-bactericidal drug concentrations may promote 
the selection of antimicrobial resistant bacteria.     
 Topical therapy is very successful when used to treat superficial ocular 
infections like conjunctivitis and keratitis.  Drug concentrations greatly exceeding the 
minimum inhibitory concentration (MIC) for most organisms are achievable.  This is 
because the drug can be directly delivered to the site of infection instead of having to 
pass through the blood-ocular-barrier and cornea (20). 
  1.4.2     Tear Film Dilution         
 One complicating factor with respect to topical application is the tear dilution.  
Each drop of antibiotic has a volume of 40-50 μl.  Because the conjunctival cul-de-sac 
only has a capacity for 20-30 μl, half of the drop volume is spilled from the eye upon 
instillation.  Between two to five minutes after the drop has been administered, the tear 
film will reduce to a normal volume of 7 to 9 μl.  Reflex tearing and blinking induced 
by instillation increases spillage onto the skin.  Some drug will also be lost via drainage 
through the nasolacrimal duct to the nose where it will be ingested.  The average tear 
production of 1 μl/minute will continue to dilute the drug resulting in a half life of 2-20 
minutes (38).  Consequently, multiple doses are needed to keep the drug concentrations 
above the MIC. 
 Instilling drops at intervals less than the five minutes it takes for the tear film to 
reach its normal volume results in a disproportionate loss of drug from the eye.  In 
circumstances where two drugs are being used for treatment, and are administered 
separately, the first agent will be displaced from the eye with rapid addition of the 
second agent (39).    
 
 15
  1.4.3     Barriers 
 Topical application for treatment of intraocular infections like endophthalmitis 
is more complicated because, in addition to dealing with the tear dilution, the drug has 
to diffuse through the cornea.  The three main layers which present the problem are the 
epithelium, stroma and endothelium.  Factors affecting the rate of diffusion are the 
drugs’ lipid and water solubility, molecular size and ionization.  Drugs that are highly 
lipophilic penetrate the epithelium easily, but are slowed down by the hydrophobic 
stroma (20).   
 Many antibacterial agents like chloramphenicol, and the fluoroquinolones, when 
applied frequently, penetrate the cornea sufficiently to achieve therapeutic 
concentrations for most organisms.  Unfortunately, accumulation of high concentrations 
of drug is prevented by the flow of aqueous humor from the ciliary process, where it is 
secreted, through the posterior and anterior chambers, and out of the eye via Schlemm’s 
canal (20).  Consequently treatment of endophthalmitis may consist of topical and 
systemic antibiotic, or topical and intravitreal application.      
  1.4.4     Resistance 
 The development of bacterial resistance to antimicrobial agents has become a 
global concern.  Infections caused by antimicrobial resistant bacteria are associated with 
higher rates of hospitalization, greater length of hospital stay, and higher rates of illness 
and death (40).  Antimicrobial resistance develops when bacteria are exposed to an 
antimicrobial agent, and selective pressure favors the growth of resistant organisms 
(41). 
 While increasing resistance rates have been observed in all of the organisms 
most commonly associated with ocular infections, the rate of antimicrobial resistant 
Gram-positive pathogens has increased the most.  Currently 25 – 30% of strains of S. 
pneumoniae in the United States have reduced susceptibilities to penicillin.  Of those 25 
– 30%, approximately 40% have intermediate resistance and 60% have full resistance 
(42).  Cross-resistance to third-generation cephalosporins, macrolides, co-trimoxazole, 
and tetracycline increases progressively in penicillin-intermediate and penicillin-
resistant strains (43).  It was shown in another study that ocular isolates collected from 
1990 – 1998 revealed the S. pneumoniae susceptibility to fluoroquinolones 
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(ciprofloxacin and ofloxacin) and aminoglycosides (tobramycin and gentamicin) was as 
low as 70% and 17% respectively (44).   
  Similar trends have been observed with S. aureus.  For example over a period 
of 12 years, the resistance rates for ciprofloxacin against methicillin-sensitive S. aureus 
(MSSA) isolated from conjunctival and corneal specimens rose from 8% to 20.7% (45).  
Another published study reported S. aureus susceptibility rates of 78 – 94% for 
gentamicin, 83 – 89% for tobramycin, 92 – 98% for ciprofloxacin and ofloxacin, and 94 
– 96% for cephalothin on corneal and conjunctival isolates collected from 1997 to 2000 
(46).   
 Gram-negative ocular pathogens like P. aeruginosa and H. influenzae have not 
had rates of resistance increase  to the same degree as Gram-positive organisms.  
Against common ocular antimicrobials such as tobramycin and gentamicin, both of 
which are aminoglycosides, P. aeruginosa susceptibilities as low as 92% and as high as 
100% have been reported(46).  With fluoroquinolones, ciprofloxacin and ofloxacin, 
susceptibility for P. aeruginosa ranges from 91% (46) to 100% (47).  H. influenzae, 
similarly, has maintained very high susceptibility rates to the fluoroquinolones (48).        
 Because fluoroquinolones are an important class of antimicrobial agents, and in 
response to increasing resistance primarily in Gram-positive organisms, two new 
fluoroquinolones have been licensed since 2003 for ophthalmic use.  Moxifloxacin was 
introduced in April of 2003 in the United States with the trade name Vigamox, and is 
available as a 0.5% ophthalmic solution.  Gatifloxacin was introduced in March of 2003 
in the United States with the trade name Zymar, and is available as a 0.3% ophthalmic 
solution.       
 1.5     Fluoroquinolones  
  1.5.1     General Overview 
 Naldixic acid, the first quinolone, was introduced in 1962.  It had good in vitro 
Gram-negative activity and was used primarily to treat uncomplicated urinary tract 
infections.  Since then, structural modifications to the core molecule have been made in 
attempts to increase the spectrum of activity of the subsequent fluoroquinolone 
compounds.  This has resulted in the development of four generations of 
fluoroquinolones which have become important in the treatment of bacterial infections.   
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 Changes made to the naphthyridone nucleus of naldixic acid, such as a 
piperazine substitution at the R7-position and fluorination at the R6-position, (Figure 
1.5) lead to the development of second generation drugs like ciprofloxacin and 
ofloxacin in the late 1980s and early 1990s (49).  They were characterized as having 
broader Gram-negative coverage, the ability to achieve high systemic concentrations 
and had some atypical pathogen coverage.  Ciprofloxacin, especially, is very active in 
vitro against clinical isolates of P. aeruginosa.  Second generation agents are indicated 
for treatment of upper and lower respiratory tract infections, uncomplicated urinary tract 
infections, sexually transmitted diseases (STD’s), nosocomial infections, gastroenteritis 
and prostatitis.  Use for treatment of community acquired pneumonia is not 
recommended due to the risk of pneumococcal bacteremia and meningitis (50).   
 Classification of third and fourth generation agents is somewhat debated.  With 
regards to systemic treatment, levofloxacin, gatifloxacin and moxifloxacin are 
considered third generation agents, while trovafloxacin is the sole fourth generation 
agent (50).  In ophthalmic circles, however, the designations are slightly different.  
Levofloxacin is a third generation agent while both moxifloxacin and gatifloxacin are 
labeled as fourth generation agents (51). 
 Structurally, levofloxacin is the L-isomer of ofloxacin.  While its Gram-negative 
activity is comparable to second generation agents like ciprofloxacin and ofloxacin, it is 
slightly more active against certain Gram-positives and atypical pathogens (52).  Fourth 
generation agents were engineered to deal with increasing fluoroquinolone resistance.  
As a result a methoxy side-chain was added to both moxifloxacin and gatifloxacin at the 
R8 position.  Moxifloxacin also has a bulky bicyclic ring attached at the R7 position 
while gatifloxacin has a methyl group on its piperazinyl ring (51).  These changes 
resulted in increased in vitro activity (i.e. lower MICs) against Streptococcus and 
Staphylococcus species.  At the same time, these compounds have been shown to be 
able to kill organisms that had shown resistance to previous fluoroquinolone 
compounds. 
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Figure 1.5:  Basic quinolone skeleton (4-oxo-1, 4 dihydroquinolone) (51) 
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 In the 1990’s, second and third generation fluoroquinolones were licensed for 
ophthalmic use (52).  Their broad spectrum activity made them good selections for first-
line topical therapy for infections like conjunctivitis and keratitis.  Ciprofloxacin and 
ofloxacin were considered comparable to popular ocular agents like chloramphenicol 
0.5%, tobramycin 0.3% and gentamicin 0.3%  for the treatment of conjunctivitis, except 
that the fluoroquinolones were able to reduce the signs and symptoms of infection more 
rapidly (53) (54).   
 With regards to aqueous and vitreous penetration, it was shown in one study that 
following a dosing regimen of one drop/15 min. x 5, then one drop/30 min. x 3 for both 
ciprofloxacin and ofloxacin resulted in aqueous concentrations of 1.13 μg/ml and 2.06 
μg/ml respectively.  Vitreous concentrations reached 0.23 μg/ml for ciprofloxacin and  
0.46 μg/ml for ofloxacin (55).  It should be noted that these results were conducted on 
patients with uncompromised corneas.  In cases with corneal ulceration, aqueous and 
vitreous drug concentrations will be even higher.  Drug concentrations in the tear film 
are much higher.  LC Green et al. (56) showed that, following the installation of two 
drops of ciprofloxacin, the drug concentration reached 2203 μg/ml at the five minute 
interval and dropped to 17.9 μg/ml after 30 minutes .                    
  1.5.2     Mechanism of Action 
 Fluoroquinolones act on two bacterial enzymes, DNA gyrase (topoisomerase II) 
and topoisomerase IV, which are both involved in bacterial DNA sythesis (51).  DNA 
gyrase is composed of two GyrA, and two GyrB monomeric subunits encoded by gyrA 
and gyrB respectively.  It is responsible for creating negative supercoils by relieving 
positive supercoils ahead of the replication fork.  This catalyzes the separation of 
daughter chromosomes; a process essential for replication (57).  Topoisomerase IV is 
composed of four homologous monomeric subunits, two ParC subunits and two ParE 
subunits encoded by parC and parE respectively (58).  This enzyme is required to 
separate linked daughter DNA molecules after replication is complete (59). 
     The enzyme specificity of second and third generation agents depends on the 
type of bacteria being targeted.  For example, against Gram-positive bacteria, 
topoisomerase IV is the primary target whereas DNA gyrase is the primary target for 
Gram-negative bacteria (60).  Fourth generation agents have been shown to exhibit dual 
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activity.  They act on both DNA gyrase and topoisomerase IV.  This may be important 
because these agents are able to kill bacteria possessing single mutations of either DNA 
gyrase or topoisomerase IV (61).             
  1.5.3     Mechanism of Resistance 
 The fluoroquinolones are subject to two main mechanisms of bacterial 
resistance:  alterations in the target enzyme binding sites, and efflux pumps.  
Alterations, via point mutations, in DNA gyrase most commonly occur in 
fluoroquinolone-resistant Gram-negative bacteria (62).  Mutations can affect either the 
GyrA or GyrB subunits but GyrA is more common (51).  Mutations tend to occur 
within a certain region of the gene known as the quinolone resistance-determining 
region (QRDR).  The QRDR is the region which encodes the portion of the GyrA 
subunit which binds to DNA during enzyme activity (63).  Mutations in topoisomerase 
IV affect either the ParC or ParE subunits, however, ParC is more common (64).  Like 
the gyrA and gryB genes, the topoisomerase point mutations in parC and parE usually 
occur in the QRDR.  These mutations are most common in fluoroquinolone-resistant 
Gram-positive bacteria (51).  Due to the single target action of second and third 
generation fluoroquinolones, single mutations significantly affect the potency of these 
drugs.  Fourth generation fluoroquinolones, however, are not as effected due to their 
dual target activity (65).      
 Efflux-mediated resistance is present in bacteria that possess special membrane 
complexes which are capable of actively pumping fluoroquinolones out of the cell.  
This allows the bacteria to survive in the presence of the drug by reducing the 
intracellular concentration to sublethal levels.  The pump’s action is dependent on its 
ability to bind to the fluoroquinolone (66).  This was considered an important factor 
when developing fourth generation fluoroquinolones.  For example, due to the bulky 
side-chain added to moxifloxacin, it is less effected by efflux mechanisms (67). 
  1.5.4 Pharmacokinetics and Pharmacodynamics 
 Because antimicrobial resistance has become a huge concern, healthcare 
professionals need to ensure that the right drugs are being used for the appropriate cases 
and formulary committees need to ensure that they are recommending effective dosing 
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regimens.  To help achieve this, certain drug characteristics, like the pharmacokinetics 
(PK) and pharmacodynamics (PD) can be analyzed .   
 Fluoroquinolones are considered to exhibit concentration-dependent killing, 
which means that as the concentration of drug increases, so does the killing effect (68).  
Other PK properties including the concentrations of drug in the serum over time, 
referred to as the area under the curve (AUC), and the peak serum concentration of the 
drug (Cmax), can be measured.  When these values are considered in combination with in 
vitro activity, predicting the microbiological and clinical outcome may be possible.  Of 
particular interest are the ratios of either Cmax to MIC or AUC to MIC resulting in the 
area under the inhibitory curve (AUIC) (69) (Fig 1.6).  Studies have identified the 
minimum AUIC values necessary to achieve the desired antimicrobial activity and 
clinical efficacy.  Higher AUIC values, such as 125, have been shown to reduce the 
emergence of resistance while even higher values have been shown to quicken bacterial 
eradication (70).  Another study done by Thomas et al. suggested that AUC/MIC should 
exceed 100 for both Gram-negative and Gram-positive species to prevent the 
development of resistance (71).          
  1.5.5     Side Effects 
 With systemic use of fluoroquinolones there is a low incidence of side effects 
which include:  nausea, headache, dizziness, rash, bitter taste, an elevation of liver 
enzymes and eosinophilia (2).  A study was done by HM Leibowitz (72) which 
investigated the side effects associated with topical ciprofloxacin therapy for 1500 cases 
of bacterial keratitis.  The following incidences of side effects were noted:  9.7% had an 
ocular burning sensation, 5% had bitter taste, 3.6% developed a white precipitate, 2% 
had a foreign body sensation, 1% experienced itching and <1% developed conjunctival 
hyperemia, chemosis and photophobia. 
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Figure 1.6:  The AUC is a universally derived formula used to predict the clinical 
success and development of resistance based on the relationship between clinical PK 
and the MIC of the particular pathogen.  The area created between the serum 
concentrations of the drug over time and MIC for a given drug and organism defines the 
AUC (73).   
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 1.6     Determining Antimicrobial Susceptibility 
  1.6.1     Minimum Inhibitory Concentration (MIC) 
 In order to ensure that antibiotics are being prescribed for organisms that are 
susceptible, routine susceptibility testing is conducted.  This is done by collecting a 
specimen and sending it to the clinical laboratory so that a pathogen may be recovered, 
identified and the MIC determined.  The MIC is defined as the lowest concentration of 
drug needed to inhibit bacterial growth when 105 colony forming units per milliliter 
(cfu/ml) are exposed to varying drug concentrations.  Based on the results from the MIC 
test, the isolate is classified as susceptible, intermediate or resistant based on guidelines 
set up by the Clinical Laboratory Standards Institute (CLSI formerly NCCLS).  The 
physician, upon receiving the results, can then decide to continue the current treatment 
or switch to a drug that is more suitable for treating the infecting pathogen(s).    
 Despite being a globally standardized and accepted test of susceptibility, there 
are some problems with MIC testing which may, in fact, be aiding the development of 
resistance.  The main problem has to do with the size of the inoculum of approximately 
105 cfu/ml, as in various human infections bacterial loads may be ≥ 109 cfu (74).  This 
becomes important when taking into account the mutation frequency of bacteria.  It has 
been reported that there is approximately one mutation for every 107 – 109 cells (75).  
With this in mind, various human infections may contain at least one resistant bacterium 
based on spontaneous mutations.  However, with an antibiotic dosing strategy based on 
MIC results, only the susceptible bacteria are taken into consideration.  With drug 
concentrations that kill susceptible organisms but not resistant bacteria, drug dosing 
may be actively selecting or enriching the resistant sub-populations (76).                       
  1.6.2     Mutant Prevention Concentration (MPC) 
 The MPC is a new type of susceptibility test that represents an attempt to 
compensate for the shortcomings of MIC testing (65).  The MPC concept is particularly 
relevant for the fluoroquinolones, as mutations occur in a step-wise manner (77).  First-
step mutations occur at a frequency of 10-7  - 10-9, and a second-step mutation occurs 
with a frequency of 10-14 or lower  (75).  Using an inoculum of 1010 cfu/ml (or ≥ 109 
cfu/ml for S. pneumoniae) which is dispensed onto agar plates with drug incorporated 
into the media, the MPC is able to more accurately approximate the concentration of 
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drug needed to eradicate a bacterial population containing both susceptible, and first-
step resistant bacteria (Fig 1.7).  Consequently, the definition of MPC is the 
“concentration of antimicrobial agent that would require an organism to possess two 
concurrent mutations to grow in the presence of that drug” (65).  Theoretically, if 
dosing strategies were to be based on the MPC concept, it would be easier to maintain 
the efficacy of the fluoroquinolones because resistant bacterial populations would be 
eliminated before they could develop into second-step mutants; organisms containing 
two concurrent mutations are resistant to all available fluoroquinolones.         
 1.7     In vitro Growth Dynamics  
  1.7.1     Kill Curves 
 While the MIC and MPC experiments determine what drug concentrations are 
required to inhibit growth of susceptible bacteria and bacteria with first-step resistance 
mutations respectively, they do not provide any information on bacterial killing.  As a 
result, another experimental approach is required to determine how long after exposure 
to an antimicrobial agent it takes for a significant bacterial population reduction to 
occur and how long this effect is maintained.  Kill curves are one approach which 
allows for the investigation of bacterial killing.  Because different locations on the body 
facilitate bacterial growth of varying loads (ex. ocular loads can reach 106 – 107 cfu 
(78), respiratory loads can reach 1010 cfu (79), kill curves are conducted with an 
inoculum size ranging from 106 to 109 cfu/ml.  Because different antimicrobial agents 
can be tested against different bacteria, comparisons of each drug’s ability to reduce 
different pathogens can be established.   
 1.8     Summary 
 Because, as humans, our lives depend so heavily on the use of our visual senses, 
any degree of damage to the visual system can have a huge impact on our quality of life.  
While bacterial eye infections do not occur with great frequency, they need to be taken 
very seriously.  Since infections can occur in every structure in the eye from the 
conjunctiva in the anterior portion to the vitreous humor in the posterior portion, we 
need to ensure we are equipped with antibiotics capable of reaching and then killing the 
infecting pathogen. 
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Figure 1.7:   First-step resistance mutants are present in bacterial cultures of 107 – 109 
cfu/ml.  Treatment at the MIC reduces only susceptible cells resulting in an enrichment 
of resistant organisms.  Treatment at the MPC should reduce both the susceptible and 
resistant populations, thereby avoiding a selective enrichment of resistant sub-
populations as seen with treatment using lower drug concentrations.  
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 The fluoroquinolones are a class of antimicrobial agents that have become 
excellent choices for use in treating ocular infections.  However, with extensive 
systemic use, improper dosing and a lack of patient compliance, rates of bacterial 
resistance have increased.  In response to the increasing resistance, particularly amongst 
Gram-positive pathogens, researchers have developed two new fluoroquinolones, 
gatifloxacin and moxifloxacin.  However, in order to convince physicians that these two 
new drugs will be a successful substitute for the existing fluoroquinolones, it needs to 
be shown that moxifloxacin and gatifloxacin have better spectra of activity while 
maintaining the ocular penetration of ofloxacin and ciprofloxacin, and the ability to 
attain a bactericidal effect in a short period of time.        
 1.9     Objectives 
 In order to address the above questions with regards to moxifloxacin and 
gatifloxacin, three objectives were established.  The first objective was to determine the 
MICs for four typical ocular pathogens (S. pneumoniae, S. aureus, H. influenzae and P. 
aeruginosa) and two atypical pathogens (Mycobacterium fortuitum and Mycobacterium 
chelonae) against five fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, 
moxifloxacin and gatifloxacin.  The second objective was to determine the MPCs for 
the same organisms against the same drugs.  The last objective was to set up kill curves 
for five fluoroquinolones against isolates of a representative Gram-positive organism (S. 
pneumoniae) and of a representative Gram-negative organism (H. influenzae).  The kill 
curves were investigated at both the MIC and MPC drug concentrations and against a 
range of inocula from 106 – 109 cfu/ml. 
 
2.0     Materials and Methods 
 2.1     Standard Laboratory Methods 
  2.1.1     Isolate Collection and Identification 
 The isolates used in this study were all ocular isolates with the exception of the 
Mycobacterium species isolates.   The Streptococcus, Staphylococcus, Pseudomonas 
and Haemophilus isolates were collected through the Clinical Microbiology Laboratory 
at Royal University Hospital as part of a provincial Health Services Utilization and 
Research Commission (HSURC) study in 2000.  Some additional Staphylococcus 
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ocular isolates were kindly provided by Dr. T. O’Brian, Wilmas Eye Institute John 
Hopkins Medical Center (Baltimore, Maryland).  All isolates were collected and 
identified using reference laboratory methods.     
  2.1.2     Isolate storage 
 All isolates used were sub-cultured onto Tryptic Soy Agar (TSA) plates 
containing 5% sheep blood (H. influenzae onto Chocolate agar plates and 
Mycobacterium species onto Middlebrook 7H11 agar plates), incubated at optimum 
temperature (35 - 37 °C) and atmospheric conditions for S. aureus and P. aeruginosa 
(5% CO2 for Streptococcus, Haemophilus and Mycobacteria) for 18 - 24 hrs.  The 
cultures were then transferred to a 1.2 ml Corning cryovial containing 0.5 ml of skim 
milk via a sterile wooden stick applicator.  The cryovials were then stored at -70 °C.   
 2.2     Susceptibility Testing 
  2.2.1     Minimum Inhibitory Concentration 
 The susceptibility testing for this project was done using the broth microdilution 
technique as recommended by the CLSI handbook (80)).  Cultures were inoculated onto 
fresh agar plates and incubated at the appropriate atmospheric conditions and 
temperature for 18 - 24 hrs.  One hundred μl of the appropriate broth was added to rows 
2-12 of a ninety-six well flat bottom microtitre plate (Mueller Hinton Broth (MHB) for 
Staphylococcus and Mycobacteria, Todd Hewitt Broth (THB) for Streptococcus, 
Pluronic Inoculum water for Haemophilus).  Two hundred μl of the antimicrobial agent 
was added to row 1 and then serially diluted through row 10.  No drug was added to 
row 11 which served as a growth control.  Each isolate was standardized to a 0.5 
McFarland standard using a colorimeter (≈ 1.0 x 108 cfu/ml).  The bacterial suspension 
was diluted 1/100 using the appropriate broth (as above except Brain Heart Infusion 
(BHI) plus 5% fildes for H. influenzae) to achieve a final concentration of  ≈ 1.0 x 106 
cfu/ml.  One hundred μl of bacterial cells was added to each well on the panel resulting 
in a final volume of 200 μl.  The purity of each isolate was checked by taking a sample 
of each isolate added to the microtitre panel and inoculating a fresh agar plate.  Both the 
purity plates and the microtitre panels were then incubated as described.  The microtitre 
panels were removed from the incubator after 16-20 hrs and read.  The results were 
considered valid if the American Type Culture Control (ATCC) strains were within the 
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susceptibility limits established by CLSI guidelines.  The ATCC strains used were S. 
pneumoniae 49619, S. aureus 29213, P. aeruginosa 27853 and H. influenzae 49247.      
 2.3     Mutant Prevention Concentration 
 Protocols for S. pneumoniae, S. aureus and P. aeruginosa were previously 
established (81, 82).  Protocols for H. influenzae, M. chelonae and M. fortuitum were 
developed as part of this thesis work.  Each organism had a corresponding ATCC 
control strain tested with initial experiments.  For example, the S. pneumoniae ATCC 
strain 49619 was tested with the S. pneumoniae isolates.        
  2.3.1     Inoculum Preparation 
 In order for this test to be run successfully, each isolate must be grown to a 
concentration ≥ 1.0 x 109 cfu/ml.  This was done slightly differently for each organism 
due to the differing growth characteristics.   Development of MPC protocols for testing 
H. influenzae and Mycobacteria involved several different steps.  First, literature 
searches were done to determine what types of media, liquid and solid, would work best 
for growing these organisms.  For H. influenzae this was HTM broth and agar, for 
Mycobacteria it was MHB with 0.02% Tween 80 for broth and MH agar supplemented 
with OADC enrichment and 5% glycerol.  Tween and glycerol were used to keep the 
Mycobacteria from clumping together.  Next, and most importantly, I needed to 
determine how to consistently get growth at ≥ 109 cfu/ml.  Aliquots of broth at 100, 
200, 300, 400 and 500 ml had two plates with confluent bacterial growth transferred 
into them and incubated for 24 hours with 5 % CO2 at 35-37°C.  The same set of broth 
aliquots were set up using three plates to inoculate from, and another set of broth for 
four, five and six plates.  After incubation viable counts were done in triplicate from 
each bottle of broth.  If bacterial counts were too low, then the samples were 
centrifuged and the pellets were re-suspended in 5 ml of broth.  Viable counts were then 
done on the concentrated samples.  For H. influenzae it was found that three plates of 
bacterial growth added to 100 ml HTM (incubated for 24 hr), then centrifuged for 20 
min. and re-suspended in 5 ml of broth gave the desired inoculum size.  For 
Mycobacteria it was found that 7.5 plates of bacterial growth added to 100 ml of broth 
(incubated 72 hr) yielded the correct sized inoculum.             
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  For S. pneumoniae, 7.5 blood agar plates were inoculated with organism using a 
sterile swab to create heavy growth and then incubated for 24 hr as described.  The 
complete contents of the plates were then transferred to 500 ml of THB using sterile 
swabs, and incubated for another 24 hr as described.  A spectrophotometer was used to 
determine the approximate bacterial population of each sample.  A bacterial suspension 
with an optical density (O.D) ≈ 0.3 at a wavelength of 600nm was required.  This 
reading is equivalent to 1.0 x 109 cfu/ml (Blondeau unpublished observations).  The 500 
ml samples were then centrifuged at 8000 rpm for 20 minutes at 4°C.  The supernatant 
was discarded and the pellets were re-suspended in 3 ml of fresh THB.  Two hundred μl 
from the 3 ml bacterial suspension was added to each of the drug dilution plates 
(preparation described in section 2.3.2) and then incubated for 48 hr as described.   
 For S. aureus and P. aeruginosa, 2.5 TSA plates were inoculated and incubated 
for 24 hr as described.  The organism was then transferred into 100 ml of fresh MHB 
and incubated for another 24 hr as described.  To achieve the necessary concentration, 
the bacterial suspension needed to achieve an O.D. reading which was ≈ 1.0 (equivalent 
to 1.0 x 109 cfu/ml) using a wavelength of 600 nm.  One hundred μl from the bacterial 
suspension was added to each of the drug dilution plates and then incubated for 48 hr as 
described.  The procedure for H. influenzae was the same except that chocolate agar 
plates were used instead of TSA, and Haemophilus Test Media (HTM) was used instead 
of MHB.  One difference between both  H. influenzae, P. aeruginosa and S. aureus, was 
that the H. influenzae and P. aeruginosa 100 ml suspensions needed to be centrifuged 
for 20 minutes at 8000 rpm at 4°C.  The pellets were re-suspended in 5 ml of MHB for 
P. aeruginosa and 5 ml HTM for H. influenzae.    
 M. chelonae and M. fortuitum strains were inoculated onto 7.5 blood agar plates 
and incubated for 72 hr at 35 – 37°C in 5 % CO2.  The cultures were then transferred to 
100 ml of MHB supplemented with 0.02% Tween 80 and incubated for 72 hr as 
described.  The bacterial suspension needed to have an O.D. reading ≈ 1.5 at 600 nm 
(equivalent to 1.0 x 109 cfu/ml).  One hundred μl of the suspension was added to each of 
the drug dilution plates and then incubated for 48 hr as described.  MPC values were 
recorded at 24 and 48 hours.   
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  2.3.2     Agar Drug Dilution Plates 
 The drug dilution plates were made using the MIC as the lowest drug dilution.  
The MIC was then doubled six times to get a total of 7 drug concentrations.  The 
amount of drug needed for each plate dilution was calculated with the following 
formula: 
 
 C1V1 = C2V2         (2.1)  
 
C1 refers to the stock concentration of the drug, C2 is the desired concentration, V1 is the 
volume of drug needed to attain the desired drug concentration and V2 is the volume of 
the agar to be poured into plates.  The plates were made from powdered agar mixed 
with the necessary ingredients, autoclaved at 121 °C for 15 minutes and then cooled to 
55 °C in a water bath.  Drug was added to the molten agar, stirred and then poured into 
sterile petri plates.  The volume poured into each plate was approximately 20 ml.  The 
agar for S. pneumoniae consisted of TSA plus 5% sheep red blood cells.  TSA was used 
for both P. aeruginosa and S. aureus.  HTM agar was used for H. influenzae, and MH 
agar supplemented with OADC enrichment and 5% glycerol was used for the 
Mycobacterium.     
  2.3.3     Reading Results 
 Once the drug plates were inoculated, the first read was done following 24hr (72 
hr for Mycobacterium) of incubation.  Each drug dilution was inspected for growth of 
individual colonies.  The results were recorded and the plates were re-incubated for 
another 24 hr (72 hr for Mycobacterium).  At that time the final results were recorded 
and the MPC was determined by the lowest dilution of drug to have no growth of 
individual colonies.  If the results were difficult to read, the plate in question was sub-
cultured onto a fresh agar plate containing the same drug concentration and incubated, 
as described, for another 24 hr (72 hr for Mycobacterium).   
 2.4     Kill Curves 
 Fresh organism was sub-cultured onto 5 TSA plates for S. pneumoniae and one 
chocolate agar plate for H. influenzae.  Plates were then incubated for 24hr as described.     
Organisms were transferred from the plates to 5 ml of broth (THB for S. pneumoniae, 
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BHI plus 5% fildes for H. influenzae) and then incubated for 2 hr as described.  Growth 
of the bacterial suspension was checked with the spectrophotometer.  An O.D. reading ≈ 
1.7 at 600 nm approximates 1.0 x 109 cfu/ml.  The 5 ml suspension was serially diluted 
by taking out 700 μl and adding it to 7 ml of fresh broth.  This was done in triplicate.  
Seven hundred μl was removed from the last tube and discarded.  This resulted in a four 
tube dilution series with inocula approximating 109, 108, 107 and 106 cfu/ml.  At this 
point the antimicrobial agent was added at either the MIC or MPC drug concentration.  
The four dilutions were vortexed and then incubated for 24 hr as described.  Samples 
from each of the four dilutions were taken at 0, 0.5, 1, 2, 4, 6, 12 and 24hr.  Samples 
consisted of 100 μl aliquots which were diluted via 1:10 dilutions and then plated in 
triplicate (100 μl added to each agar plate).  The samples were diluted so that viable 
counts had a countable number of colonies (20-200).  The plates were then incubated 
for 24 hr as described.  The 24 hr sample was taken, and the plates which had been 
inoculated with the 0 to 12 hr samples were read to determine the colony counts.  The 
24 hr sample was read following 24 hr of incubation as described.       
 
3.0     Results 
 3.1     MIC Results for Ocular Isolates 
 The goal of this project was to examine the in vitro potency of five 
fluoroquinolones, using different methods, to eradicate organisms associated with 
ocular infections.  For my experiments, two of the most common Gram-positive ocular 
pathogens (S. pneumoniae, S. aureus), two of the most common Gram-negative ocular 
pathogens (H. influenzae, P. aeruginosa) and two atypical ocular pathogens (M. 
chelonae, M. fortuitum) were selected for testing.  Because ocular specimens are not 
routinely collected, the number of clinical isolates for each organism was rather limited.  
Consequently, the following number of isolates were collected and tested:  38 S. 
pneumoniae, 8 S. aureus, 22 P. aeruginosa, 31 H. influenzae, 5 M. fortuitum and 4 M. 
chelonae.   
 The MIC results were summarized by calculating the MIC50, the modal value, 
and the MIC90.  The MIC50 represents the concentration of drug required to inhibit 50% 
of the isolates tested.  Likewise, the MIC90 represents the concentration of drug required 
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to inhibit 90% of the isolates tested.  The results are displayed by showing the MIC 
distribution and then by calculating the MIC50 and MIC90 values for each organism.  For 
organisms where fewer than 10 isolates were tested the MIC50 and MIC90 values were 
not calculated.   
 It was expected that the new fluoroquinolones (moxifloxacin, gatifloxacin) 
would show more in vitro potency against the Gram-positive organisms than the older 
fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin).  The results supported this 
hypothesis.  For S. pneumoniae, the MIC distribution showed the newer 
fluoroquinolones furthest to the left at the lower drug concentrations while the older 
fluoroquinolones shifted considerably to the right towards the higher drug 
concentrations (Table 3.1.1).  For moxifloxacin, the majority of isolates had values of 
either 0.063 or 0.125 μg/ml.  In this case both the MIC50 and MIC90 were identical with 
a value of 0.125 μg/ml.  For gatifloxacin the results were slightly higher than 
moxifloxacin with the majority of isolates having MIC values of either 0.125 or 0.25 
μg/ml.  Again, both the MIC50 and MIC90 were the same, having a value of 0.25 μg/ml 
(one dilution higher than moxifloxacin).  The MIC values for levofloxacin were 
between 4 and 8-fold higher than moxifloxacin and gatifloxacin.  Roughly half of the S. 
pneumoniae isolates tested against levofloxacin had MIC values of either 0.5 or 1 
μg/ml.  In this case there was a one dilution difference between the MIC50 (0.5 μg/ml) 
and the MIC90 which was 1 μg/ml.  The results for ofloxacin and ciprofloxacin were 
very similar.  They had the highest MIC values of the five fluoroquinolones tested.  
Ofloxacin, however, had a higher number of isolates with values of 2 μg/ml.  This 
difference was reflected in the MIC50, which was 2 μg/ml for ofloxacin and 1 μg/ml for 
ciprofloxacin.  The MIC90 values were identical at 2 μg/ml.  Overall, for S. pneumoniae, 
the rank order of potency was moxifloxacin > gatifloxacin > levofloxacin > 
ciprofloxacin > ofloxacin.   
 A similar trend was observed with S. aureus, except there was not as large a 
difference between the older and newer fluoroquinolones.  The MIC distribution 
showed a gradual increase in MIC values as the progression from newer to older 
fluoroquinolones was made (Table 3.1.2).  Moxifloxacin had MIC values ranging from 
0.016 to 0.031 μg/ml, with 63% of isolates at the higher dilution.  Gatifloxacin had MIC 
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values which were 1-2 dilutions higher than those for moxifloxacin.  The values ranged 
from 0.063 – 0.125 μg/ml with, 75% of isolates having the lower value as their MIC.  
Levofloxacin was only slightly less potent than gatifloxacin with 7 out of 8 isolates 
having an MIC of 0.125 μg/ml.  The results for ofloxacin and ciprofloxacin were, again, 
similar.  Both fluoroquinolones had MIC90 values of 0.25 μg/ml.  For ciprofloxacin two 
isolates had MIC values of 0.125 μg/ml.  As a result, the rank of potency between the 
five drugs for S. aureus was moxifloxacin > gatifloxacin  > levofloxacin > ciprofloxacin 
> ofloxacin.   
 For the Gram-negative organisms it was expected that the new fluoroquinolones 
would maintain the same activity as the older fluoroquinolones; this was not the case.  
For H. influenzae, the distribution had a much different appearance than that of the 
Gram-positives (Table 3.1.3).  While the ranges differed somewhat between the five 
fluoroquinolones the MIC50 and MIC90 values were essentially identical.  There was a 
large range of MIC values for moxifloxacin, from 0.004 – 0.063 μg/ml.  The MIC90 
value (0.031 μg/ml ) was only one dilution higher than the MIC50 value (0.016 μg/ml).  
Gatifloxacin had a slightly narrower range with MIC values of 0.008 – 0.031 μg/ml.  
The MIC50 and MIC90 values, however, were identical to that of moxifloxacin.  The 
range of MIC values for levofloxacin was 0.002 – 0.031 μg/ml.  With both an MIC50 
and MIC90 0.016 μg/ml, the values for levofloxacin were lower than that of 
moxifloxacin and gatifloxacin.  It was expected that results for ofloxacin would 
resemble that of ciprofloxacin but this was not the case.  The MIC distribution for 
ofloxacin was similar to that of moxifloxacin.  The MIC values ranged from 0.008 – 
0.063 μg/ml.  The MIC50 and MIC90 values were 0.016 and 0.031 μg/ml  respectively.  
Ciprofloxacin was the most potent of the five fluoroquinolones.  The MICs ranged from 
0.001 – 0.016 μg/ml.  The MIC50 value was lower than the other fluoroquinolones by
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Drug n 0.031 0.063 0.125 0.25 0.5 1 2 4 MIC50a MIC90a
Moxifloxacin 38 1 15 21 1 0.125 0.125
Gatifloxacin 38 1 15 20 2 0.25 0.25
Levofloxacin 38 20 18 0.5 1
Ofloxacin 38 10 27 1 2 2
Ciprofloxacin 38 6 21 9 2 1 2
MIC Distribution (ug/ml)
 
Table 3.1.1:  Summary of the in vitro potency of the five fluoroquinolones tested against ocular S. pneumoniae isolates. 
a The drug concentration inhibiting 50% and 90% of isolates tested respectively. 
MIC = the Minimum Inhibitory Concentration. 
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Drug n 0.016 0.031 0.063 0.125 0.25 0.5
Moxifloxacin 8 3 5
Gatifloxacin 8 6 2
Levofloxacin 8 7 1
Ofloxacin 8 7 1
Ciprofloxacin 8 2 5 1
MIC Distribution (ug/ml)
 
 
Table 3.1.2:  Summary of the in vitro potency of the five fluoroquinolones tested against ocular S. aureus isolates. 
MIC = the Minimum Inhibitory Concentration.  The MIC50 and MIC90 values were not calculated as the number of isolates tested was 
less than 10. 
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Drug n 0.001 0.002 0.004 0.008 0.016 0.031 0.063 MIC50a MIC90a
Moxifloxacin 31 7 7 12 4 1 0.016 0.031
Gatifloxacin 31 15 9 7 0.016 0.031
Levofloxacin 31 1 4 9 15 2 0.016 0.016
Ofloxacin 31 1 21 8 1 0.016 0.031
Ciprofloxacin 31 1 4 5 14 7 0.008 0.016
MIC Distribution (ug/ml)
 
 
Table 3.1.3:  Summary of the in vitro potency of the five fluoroquinolones tested against ocular H. influenzae isolates. 
a The drug concentration inhibiting 50% and 90% of isolates tested respectively. 
MIC = the Minimum Inhibitory Concentration. 
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Drug n 0.063 0.125 0.25 0.5 1 2 4 8 16 32 MIC50a MIC90a
Moxifloxacin 21 1 2 10 2 4 2 1 1 8
Gatifloxacin 21 3 7 5 3 2 1 1 4
Levofloxacin 21 1 3 5 6 4 2 1 1 4
Ofloxacin 21 3 7 5 4 2 1 2 8
Ciprofloxacin 21 4 4 6 5 1 1 1 0.25 1
MIC Distribution (ug/ml)
 
 
Table 3.1.4:  Summary of the in vitro potency of the five fluoroquinolones tested against ocular P. aeruginosa isolates. 
a The drug concentration inhibiting 50% and 90% of isolates tested respectively. 
MIC = the Minimum Inhibitory Concentration. 
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Drug n 0.25 0.5 1 2 4 8 >16
Moxifloxacin 4 1 2 1
Gatifloxacin 4 1 1 2
Levofloxacin 4 1 1 2
Ofloxacin 4 1 3
Ciprofloxacin 4 1 1 2
MIC Distribution (ug/ml)
 
Table  3.1.5:  Summary of the in vitro potency of the five fluoroquinolones tested against systemic M. chelonae isolates. 
MIC = the Minimum Inhibitory Concentration.  The MIC50 and MIC90 values were not calculated as the number of isolates tested was 
less than 10.   
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Drug n 0.125 0.25 0.5 1 2 4
Moxifloxacin 5 2 2 1
Gatifloxacin 5 1 2 1 1
Levofloxacin 5 1 3 1
Ofloxacin 5 2 2 1
Ciprofloxacin 5 3 1 1
MIC Distribution (ug/ml)
 
 
Table 3.1.6:  Summary of the in vitro potency of the five fluoroquinolones tested against systemic M. fortuitum isolates. 
MIC = the Minimum Inhibitory Concentration.  The MIC50 and MIC90 values were not calculated as the number of isolates tested was 
less than 10. 
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Figure 3.1.7:  Fluoroquinolone breakpoints (80).  Intermediate and resistant values 
were not available for H. influenzae.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organism Drug Susceptible Intermediate Resistant
S. aureus Ciprofloxacin <1 2 >4
Levofloxacin <2 4 >8
Gatifloxacin <2 4 >8
S. pneumoniae Gatifloxacin <1 2 >4
Levofloxacin <2 4 >8
Moxifloxacin <1 2 >4
H. influenzae Ciprofloxacin <1
Gatifloxacin <1
Levofloxacin <2
Moxifloxacin <1
Ofloxacin <2
P. aeruginosa Ciprofloxacin <1 2 >4
Levofloxacin <2 4 >8
Ofloxacin <2 4 >8
Gatifloxacin <2 4 >8
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one dilution, with a value of 0.008 μg/ml.  The MIC90 value was 0.016 μg/ml, which 
was the same as for levofloxacin.  Despite the minor differences, all five 
fluoroquinolones were potent in vitro with 100% of isolates inhibited by ≤ 0.063 μg/ml 
of any drug.  The rank order of potency was ciprofloxacin = levofloxacin > ofloxacin = 
gatifloxacin = moxifloxacin. 
The MIC distribution for P. aeruginosa showed a large MIC range for each of 
the quinolones (Table 3.1.4).  For moxifloxacin the range of MIC values was 0.25 – 32 
μg/ml.  The largest number of isolates (47%) had an MIC value of 1 μg/ml (MIC50) 
whereas the MIC90 value was 8-fold higher at 8 μg/ml.  For gatifloxacin the MIC range 
was 0.25 – 8 μg/ml.  While the largest number of isolates (33%) had an MIC value 0.5 
μg/ml, one dilution lower than for moxifloxacin, the MIC50 values were the same at 1 
μg/ml.  The MIC90 however, was one dilution lower at 4 μg/ml.  Levofloxacin had one 
of the widest ranges with MIC values from 0.125 – 32 μg/ml.  Like gatifloxacin, 
levofloxacin had MIC50 and MIC90 values of 1 and 4 μg/ml respectively.  Surprisingly 
ofloxacin had the lowest potency.  The MIC values ranged from 0.5 – 32 μg/ml.  While 
the majority of isolates had MICs of 1 μg/ml the MIC50 was 2 μg/ml.  The MIC90 was 
the same as for moxifloxacin at 8 μg/ml.  Ciprofloxacin had the most potent in vitro 
activity with MIC values 4 – 8-fold lower than that of the other fluoroquinolones.  The 
MIC range was 0.063 – 16 μg/ml and MIC50 and MIC90 values of 0.25 and 1 μg/ml 
respectively.  While ciprofloxacin’s in vitro potency was significantly better than the 
others, the four other fluoroquinolones had quite similar MIC values.  The rank order of 
potency for P. aeruginosa was ciprofloxacin > levofloxacin = gatifloxacin > ofloxacin = 
moxifloxacin.    
 For the atypical mycobacteria, it was expected that the new fluoroquinolones 
would have lower MICs compared to the older fluoroquinolones.  This turned out to be 
the case, except that ciprofloxacin showed equivalent activity as shown in tables 3.1.5 
and 3.1.6.  Due to the low number of isolates only loose observations can be made.  For 
M. chelonae, moxifloxacin, gatifloxacin and ciprofloxacin appeared to have similar 
potency with the majority of the isolates having MIC values of 4 – 8 μg/ml.  Both 
levofloxacin and ofloxacin seemed to have slightly less in vitro potency with the 
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majority of the isolates having MIC values ≥ 16 μg/ml.  The resulting rank order of 
potency was moxifloxacin = gatifloxacin = ciprofloxacin > levofloxacin = ofloxacin.      
The MIC trends for M. fortuitum were similar to that of M. chelonae, except that 
the MIC values seemed to be lower.  For moxifloxacin, gatifloxacin and ciprofloxacin, 
the majority of the MIC values were between 0.125 and 0.25 μg/ml.  Both levofloxacin 
and ofloxacin had MIC values between 1 and 2 μg/ml which was approximately 2-fold 
higher than the other fluoroquinolones.  The rank order of potency for M. fortuitum was 
moxifloxacin = gatifloxacin = ciprofloxacin > levofloxacin = ofloxacin.                        
 3.2     MPC Results for Ocular Isolates 
 The MPC results showed the same trends as did the MIC results.   The number 
of ocular isolates tested using MPC fluctuated from test to test.  This is because, at least 
for the fastidious organisms like S. pneumoniae and H. influenzae, it was difficult to get 
the organisms to grow to an inoculum size ≥ 109 cfu/ml as required for the MPC test.  
While all ocular isolates were tested, only the results from the experiments which 
attained the proper inoculum size were included in the summary.  The results were 
summarized by calculating the MPC50 and MPC90.  The MPC50 represents the 
concentration of drug required to prevent the growth of first-step mutants for 50% of the 
isolates tested.  MPC90 represents the concentration of drug required to inhibit the 
growth of first-step mutants for 90% of the bacterial isolates tested.     
     Based on previous observations from our laboratory it was anticipated that the 
MPC values would be higher than those from the MIC testing because it should be 
harder to inhibit a population of bacteria which, firstly, is larger than that used in MIC 
testing, and second, that may possess first-step resistance mutations.  It was also 
expected that the rank order of potency established by MIC would be maintained for the 
MPC results.   For the most part, both of these working assumptions were correct.  
Starting with clinical eye isolates of S. pneumoniae, the newer fluoroquinolones 
showed four to eight times the potency compared to the older fluoroquinolones.  The 
moxifloxacin MPC values ranged from 0.125 – 1 μg/ml (Table 3.2.1).  The vast 
majority of isolates (56%) had MPC values of 0.5 μg/ml, which was the same as the 
MPC50.  The MPC90 was one dilution higher at 1 μg/ml.  The results for gatifloxacin 
were similar.  The range, however, was much narrower, with MPC values from 0.5 – 2 
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μg/ml.  The MPC50 value was 1 μg/ml, one dilution higher than that of moxifloxacin.  
The MPC90 was also 1 μg/ml, the same as for moxifloxacin.  The results for 
levofloxacin showed a slight shift to the right in the MPC distribution.  The MPC values 
ranged from 1 – 4 μg/ml.  The MPC50 value was 2 μg/ml while the MPC90 value was 2-
fold higher at 4 μg/ml.  The results for both ofloxacin and ciprofloxacin were identical 
except that the range for ciprofloxacin extended from 2 – 16 μg/ml as opposed to 2 – 8 
μg/ml for ofloxacin.  Both had MPC50 values of 4 μg/ml and MPC90 values of 8 μg/ml.  
The rank potency order was moxifloxacin = gatifloxacin > levofloxacin > ciprofloxacin 
= ofloxacin. 
 The S. aureus results, like S. pneumoniae, showed a gradual shift in the MPC 
distribution to the right with the progression of newer to older fluoroquinolones (Table 
3.2.2).  Moxifloxacin appeared to have the most in vitro potency with lower MPC 
values.  All of the MPC values were 0.125 μg/ml.  Gatifloxacin had MPC values of 0.25 
μg/ml, one dilution greater than moxifloxacin and levofloxacin was 2-fold less active 
than gatifloxacin having MPC values of 0.5 μg/ml.  The majority of isolates tested 
against ofloxacin had MPC values of 1 μg/ml.  Ciprofloxacin was 2-fold less potent 
than ofloxacin with the majority of isolates having MPC values of 2 μg/ml.  From the 
newest fluoroquinolone to the oldest, there was one dilution decrease in in vitro potency 
resulting in a potency rank order of moxifloxacin > gatifloxacin > levofloxacin > 
ofloxacin > ciprofloxacin. 
 All five fluoroquinolones were very effective in vitro against H. influenzae.  For 
moxifloxacin, there was a range of MPC values from 0.063 – 0.5 μg/ml (Table 3.2.3).  
The majority (42%) of the isolates had MPC values of 0.5 μg/ml.  The MPC50 was 0.25 
μg/ml with the MPC90 one concentration higher at 0.5 μg/ml.  The results for 
gatifloxacin were slightly lower with a range of MPC values from 0.063 – 0.25 μg/ml.  
Both the MPC50 and MPC90 values were 0.125 μg/ml.  For levofloxacin, the MPC 
values were identical to that of gatifloxacin.  Ofloxacin had the same MPC values as 
moxifloxacin with an MPC50 of 0.25 μg/ml and a MPC90 of 0.5μg/ml.  The distribution 
was slightly different with values ranging from 0.125 - ≥ 1 μg/ml.  Ciprofloxacin had 
the widest distribution with MPC values from 0.063 - ≥ 1 μg/ml.  The MPC50 and 
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MPC90 values were 0.125 and 0.5 μg/ml respectively.  The rank order of potency was 
gatifloxacin = levofloxacin > ciprofloxacin > moxifloxacin = ofloxacin.   
 Overall, the MPC values for P. aeruginosa were considerably higher than those 
observed for the other pathogens (Table 3.2.4).  Moxifloxacin exhibited the least in 
vitro potency with an MPC distribution ranging from 8 - ≥ 64 μg/ml.  The MPC50 value 
was 16 μg/ml while the MPC90 value was 2-fold higher at 32 μg/ml.  Gatifloxacin had 
MPC values which were marginally lower and the MPC distribution ranged from 4 – 32 
μg/ml.  With the majority (52%) of the isolates having an MPC value of either 4 or 8 
μg/ml, both the MPC50 and MPC90 values were 8 μg/ml.  The MPC results for 
levofloxacin were the same as for gatifloxacin, both the MPC50 and MPC90 were 8 
μg/ml.  Ofloxacin had an MPC distribution of 8 - ≥ 64 μg/ml, similar to the results 
observed for moxifloxacin.  Both the MPC50 and MPC90 values were 16 μg/ml.  
Ciprofloxacin exhibited the greatest in vitro potency with an MPC range of 1 - 16μg/ml; 
the MPC50 and MPC90 values were 2 μg/ml.  Ciprofloxacin was between 4 and 16 times 
as potent as the other fluoroquinolones.  The in vitro rank potency order was 
ciprofloxacin > gatifloxacin = levofloxacin > ofloxacin > moxifloxacin.                   
 The results for the MPC testing of the 5 fluoroquinolones against atypical 
mycobacterial strains are summarized in tables 3.2.5 and 3.2.6.  With regards to M. 
chelonae, there was a wide MPC distribution for all fluoroquinolones.  For 
moxifloxacin, the MPC values ranged from 4 – 256 μg/ml with each isolate having a 
different MPC value.  The MPC results for gatifloxacin showed a range from 32 – 256 
μg/ml, however, all but one of the isolates had an MPC value of 32 μg/ml.  
Levofloxacin also had a wide MIC range with MPC values of 16 - ≥ 512 μg/ml.  
Ofloxacin had MPC values were only spread over three dilutions ranging from 64 – 256 
μg/ml.  Ciprofloxacin had a slightly narrower MPC distribution with values from 8 – 
128 μg/ml.  The rank of potency order was ciprofloxacin > moxifloxacin = gatifloxacin  
=ofloxacin>levofloxacin.
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Drug n 0.125 0.25 0.5 1 2 4 8 16 MPC50a MPC90a
Moxifloxacin 33 4 2 19 7 1 0.5 1
Gatifloxacin 31 9 19 3 1 1
Levofloxacin 33 5 23 5 2 4
Ofloxacin 37 3 20 14 4 8
Ciprofloxacin 32 5 20 4 3 4 8
MPC Distribution (ug/ml)
 
 
Table 3.2.1:  Summary of the in vitro potency as determined by MPC testing of five fluoroquinolones tested against ocular S. 
pneumoniae isolates. 
a The drug concentration inhibiting 50% and 90% of isolates tested respectively. 
MPC = the Mutant Prevention Concentration. 
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Drug n 0.125 0.25 0.5 1 2 4
Moxifloxacin 8 8
Gatifloxacin 8 8
Levofloxacin 8 8
Ofloxacin 8 7 1
Ciprofloxacin 8 3 4 1
MPC Distribution (ug/ml)
 
 
Table 3.2.2:  Summary of the in vitro potency as determined by MPC testing of five fluoroquinolones tested against ocular S. 
aureus isolates. 
MPC = the Mutant Prevention Concentration.  The MPC50 and MPC90 values were not calculated as the number of isolates tested was 
less than 10. 
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Drug n 0.063 0.125 0.25 0.5 >1 MPC50a MPC90a
Moxifloxacin 26 1 7 7 11 0.25 0.5
Gatifloxacin 26 9 16 1 0.125 0.125
Levofloxacin 25 2 22 1 1 0.125 0.125
Ofloxacin 26 2 18 5 1 0.25 0.5
Ciprofloxacin 26 5 13 6 2 0.125 0.5
MPC Distribution (ug/ml)
 
 
Table 3.2.3:  Summary of the in vitro potency as determined by MPC testing of five fluoroquinolones tested against ocular H. 
influenzae isolates. 
a The drug concentration inhibiting 50% and 90% of isolates tested respectively. 
MPC = the Mutant Prevention Concentration.  
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Drug n 1 2 4 8 16 32 >64 MPC50a MPC90a
Moxifloxacin 21 1 10 8 2 16 32
Gatifloxacin 21 8 11 2 8 8
Levofloxacin 21 4 15 2 8 8
Ofloxacin 21 5 14 2 16 16
Ciprofloxacin 21 3 15 1 1 2 2 2
MPC Distribution (ug/ml)
 
 
Table 3.2.4:  Summary of the in vitro potency as determined by MPC testing of five fluoroquinolones tested against ocular P. 
aeruginosa isolates. 
a The drug concentration inhibiting 50% and 90% of isolates tested respectively. 
MPC = the Mutant Prevention Concentration.  
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Drug n 4 8 16 32 64 128 256 >512
Moxifloxacin 4 1 1 1 1
Gatifloxacin 4 3 1
Levofloxacin 4 2 1 1
Ofloxacin 4 1 1 2
Ciprofloxacin 4 1 2 1
MPC Distribution (ug/ml)
 
 
Table 3.2.5:  Summary of the in vitro potency as determined by MPC testing of five fluoroquinolones tested against systemic 
M. chelonae isolates. 
MPC = the Mutant Prevention Concentration.  The MPC50 and MPC90 values were not calculated as the number of isolates tested was 
less than 10. 
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Drug n 0.5 1 2 4 8
Moxifloxacin 5 2 1 2
Gatifloxacin 5 1 3 1
Levofloxacin 5 4 1
Ofloxacin 5 2 3
Ciprofloxacin 5 2 3
MPC Distribution (ug/ml)
 
Table 3.2.6: Summary of the in vitro potency as determined by MPC testing of five fluoroquinolones tested against systemic M. 
fortuitum isolates. 
MPC = the Mutant Prevention Concentration.  The MPC50 and MPC90 values were not calculated as the number of isolates tested was 
less than 10. 
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All five fluoroquinolones had much lower MPCs against M. fortuitum than 
against M. chelonae.   The MPC distribution for moxifloxacin and gatifloxacin extended 
from 0.5 to 2 μg/ml.   Levofloxacin and ofloxacin had higher MPC values ranging from 
4 – 8 μg/ml .  Ciprofloxacin had similar values to moxifloxacin and gatifloxacin with an 
MPC distribution of 1 – 2 μg/ml.  The rank of potency order was moxifloxacin = 
gatifloxacin = ciprofloxacin > ofloxacin = levofloxacin.                            
 3.3     Kill Curve Results for Ocular Isolates 
 Kill curve experiments were conducted to examine the bactericidal activities of 
the five fluoroquinolones against bacterial inocula ranging from 106 – 109 cfu/ml.  
Current literature presents kill curve data using inoculum sizes of 105 - 106cfu/ml.  
However, because actual bacterial loads of an ocular infection may reach 106 cfu or 107 
cfu it was decided that the tests should incorporate a range of inoculum sizes (78).  
Because S. pneumoniae and H. influenzae are some of the most common pathogens of 
their respective Gram-positive and Gram-negative classes, they were selected as the 
most representative organisms to be tested.  The sample size was initially set at seven, 
as seen in the S. pneumoniae MPC kill curves for gatifloxacin and moxifloxacin (Tables 
3.3.1.3 and 3.3.1.7), however, due to the fastidious nature of this organism, a smaller 
sample size of four isolates was much more feasible given the time lines available for 
this project.  That same number of organisms was used for testing H. influenzae.  The 
drug concentrations used for these experiments were set using two different sets of 
parameters.  The first was using the pre-determined MIC value for each isolate.  
Because the MIC value is such a globally used measurement, it was thought that it 
would be important to examine the pharmacodynamic properties for this set of drug 
concentrations.  The second parameter used was the pre-determined MPC values for 
each isolate.  Because it has been argued (65) that the MPC model provides a much 
more realistic drug concentration needed for eradication of a heterogeneous bacterial 
population (including both susceptible and first-step resistant organisms), it was 
important to have pharmacodynamic results at the MPC drug concentration to compare 
to the traditional MIC measurements.          
 
 52
  3.3.1     S. pneumoniae 
 The S. pneumoniae kill results for moxifloxacin at the MIC are summarized in 
tables 3.3.1.1, and 3.3.1.2 (Fig. 3.3.1.3 – 3.3.1.8).  At six hours there was a > 90 % 
reduction in viable cells at 107 cfu/ml, which is equivalent to a > 2 log reduction (Fig. 
3.3.1.3).  It was not until 12 hours that we see this same reduction with the other 
inocula.  At 24 hours the reduction in viable cells is more pronounced for the 108 and 
109 cfu/ml inocula, however, re-growth was seen at 106 and 107 cfu/ml.  At the MPC 
drug concentration, killing begins much sooner as shown in table 3.3.1.4 (Fig. 3.3.1.4 – 
3.3.1.8).  As early as two hours after drug exposure, there was a 91% reduction in viable 
cells at the 107 cfu/ml inoculum.  By four hours, three of the lower inocula reached a > 
98 % viable cell reduction while it was not until 12 hours that moxifloxacin achieved 
this with the 109 cfu/ml inoculum.  Unlike the results for the MIC kill curves, the killing 
at the MPC continued right up until 24 hours at which time all inocula were reduced by 
100%. 
 The results for gatifloxacin at the MIC drug concentration are shown in table 
3.3.1.6 (Fig. 3.3.1.3 – 3.3.1.8).  At 106 cfu/ml, re-growth was observed immediately and 
continued throughout the 24 hours except for the slight viable cell reduction that 
occurred between the 0.5 and 1 hour interval.  At 107 cfu/ml, a slight viable cell 
reduction of 40% was achieved by 6 hours, however, it was followed by re-growth 
which continued to the end of the test period.  The 108 cfu/ml inoculum began with 
growth that continued until the 6 hour interval.  At 12 hours a reduction in cell number 
was noticed.  This trend continued, and by 24 hours a 83% reduction in viable cells had 
occurred.   At 109 cfu/ml there was a decrease in viable cells immediately following 
drug exposure which continued until it reached a ≥ 99.99% (>3 log reduction Fig. 
3.3.1.7) reduction by 24 hours.  At the MPC drug concentration, an overall reduction in 
viable cells was observed much sooner than with the MIC (Table 3.3.1.8)  For the lower 
three inocula there was a ≥ 98% reduction by 4 hours which reached 100% by 24 hours.  
As with the moxifloxacin MPC kill results, the 109 cfu/ml inoculum had a reduction in 
viable cells that occurred at a slower rate than that seen with the lower inocula.   By 12 
hours, the reduction in viable cells was ≥ 99%. 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.003 -0.2 -0.4 -0.81 -1.14 -1.7 -1.3
10^7 0.057 -0.23 -0.44 -1.15 -1.46 -2.08 -0.69
10^8 0.07 -0.04 -0.12 -0.097 -0.34 -1.07 -1.56
10^9 0.005 -0.025 -0.09 -0.24 -0.49 -2.12 -4.24
Ave. Log Reduction
 
 
Table 3.3.1.1:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to moxifloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates  = 0.063 – 0.125 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -0.48 -22.81 -29.18 -74.71 -84.81 -95.8 -92.6
10^7 13.86 -25.64 -68.58 -77.9 -96.49 -99.14 -62.31
10^8 16.2 7.8 34.43 20.21 -48.44 -90.43 -95.48
10^9 0.67 -4.66 -15.88 -40.44 -67.19 -99.23 -99.99
Ave. Percentage Reduction
 
 
Table 3.3.1.2:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to moxifloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.063 – 0.125 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.13 -0.38 -1.25 -2.04 -3.25 -3.98 -5.08
10^7 -0.019 -0.51 -1.28 -2.1 -3.08 -3.98 -5.12
10^8 -0.12 -0.32 -1.11 -2.3 -2.98 -3.63 -5.82
10^9 -0.074 -0.071 -0.54 -0.94 -1.36 -3.51 -6.44
Ave. Log Reduction
 
 
Table 3.3.1.3:  The average log10 reduction in viable cells of 7 clinical S. 
pneumoniae isolates exposed to moxifloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 7 isolates = 0.25 – 0.5 μg/ml 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -19.98 -55.01 -89.69 -98.4 -99.66 -99.98 -100
10^7 -27.79 -64.24 -91.29 -99.1 -98.4 -99.99 -100
10^8 -18.14 -56.44 -87.83 -99.16 -99.78 -99.82 -100
10^9 -14.94 -24.22 -53.27 -77.78 -88.72 -99.55 -100
Ave. Percentage Reduction
 
 
Table 3.3.1.4:  The average percentage reduction in viable cells of 7 clinical S. 
pneumoniae isolates exposed to moxifloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 7 isolates = 0.25 – 0.5 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.03 -0.033 -0.058 -0.19 0.66 1.27 0.32
10^7 -0.03 -0.05 -0.21 -0.28 -0.35 0.38 -0.07
10^8 0.07 0.055 0.21 0.22 0.048 -0.84 -1.8
10^9 -0.83 -0.83 -0.83 -1.06 -1.08 -1.8 -3.85
Ave. Log Reduction
 
 
Table 3.3.1.5:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to gatifloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates  = 0.125 – 0.25 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 7.49 -1.19 13.86 36.76 78.25 94.32 50.81
10^7 -9.38 -0.038 -28.87 -34.13 -39.26 52.73 15.32
10^8 15.23 10.79 37.9 38.13 8.01 -33 -83.33
10^9 -85.07 -85.33 -85.22 -91.3 -91.59 -98.42 -99.99
Ave. Percentage Reduction
 
 
Table 3.3.1.6:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to gatifloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.125 – 0.25 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.12 -0.28 -1 -2.16 -2.86 -4.39 -5.75
10^7 -0.21 -0.46 -1.23 -2.5 -3.3 -5.56 -6.84
10^8 -0.12 -0.36 -0.9 -2.23 -2.78 -3.46 -5.79
10^9 -0.004 -0.12 -0.49 -0.6 -1.05 -3.28 -7.77
Ave. Log Reduction
 
Table 3.3.1.7:  The average log10 reduction in viable cells of 7 clinical S. 
pneumoniae isolates exposed to gatifloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 7 isolates = 0.5 – 2 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -13.07 -32.07 -80.51 -98.05 -99.53 -99.97 -100
10^7 -20.43 -39.47 -84.72 -99.56 -99.86 -99.99 -100
10^8 -19.53 -43.93 -82.43 -98.77 -99.82 -99.75 -100
10^9 -0.47 -12.98 -31.9 -57.07 -80.41 -99.83 -99.99
Ave. Percentage Reduction
 
Table 3.3.1.8:  The average percentage reduction in viable cells of 7 clinical S. 
pneumoniae isolates exposed to gatifloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 7 isolates = 0.5 – 2 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.083 -0.05 -0.16 -0.71 -0.9 -1.8 -0.24
10^7 -0.073 -0.075 -0.26 -1.28 -1.63 -2.14 -1.57
10^8 0.015 -0.023 -0.23 -0.49 -0.58 -0.88 -2.09
10^9 -0.008 -0.015 -0.03 -0.22 -0.62 -2.59 -4.26
Ave. Log Reduction
 
 
Table 3.3.1.9:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to levofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.5 – 1 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -16.79 -8.95 -15.13 -69.47 -71.59 -90.31 39.03
10^7 -11.45 -14.69 -38.98 -89.42 -95.29 -97.53 -97
10^8 3.47 -3.2 -34.93 -48.46 -46.19 -72.84 -94.63
10^9 2.75 -1.97 -6.36 -54.89 -74.59 -99.31 -99.99
Ave. Percentage Reduction
 
 
Table 3.3.1.10:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to levofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.5 – 1 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.02 -0.115 -1.04 -1.77 -2.19 -3.72 -5.15
10^7 -0.025 -0.235 -1.07 -2.03 -2.83 -4.64 -6.37
10^8 -0.063 -0.22 -1.23 -2.14 -2.72 -3.19 -5.1
10^9 0.0125 -0.143 -0.263 -0.57 -1.46 -2.32 -5.58
Ave. Log Reduction
 
Table 3.3.1.11:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to levofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 2 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -3.71 -18.91 -88.41 -95.55 -98.84 -99.97 -100
10^7 -16.08 -39.5 -88.5 -98.91 -99.84 -100 -100
10^8 -12.26 -34.31 -91.37 -99.11 -99.74 -99.94 -100
10^9 12.52 -27.06 -44.08 -67.31 -92.36 -99.23 -100
Ave. Percentage Reduction
 
Table 3.3.1.12:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to levofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 2 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.07 -0.085 -0.31 -0.6 -1.21 -1.86 -2.29
10^7 -0.008 -0.035 -0.23 -0.89 -1.62 -3 -1.46
10^8 0.0025 -0.018 -0.47 -0.38 -0.5 -1.31 -1.82
10^9 -0.025 -0.058 -0.113 -0.53 -1.17 -3 -5.06
Ave. Log Reduction
 
 
Table 3.3.1.13:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 1 – 2 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 15.23 -15.72 -44.32 -58.96 -76.43 -58.1 -99.2
10^7 -0.82 -7.25 -34.65 -68.53 -90.87 -99.75 -95.77
10^8 1.12 -2.72 -45 -45.37 -61.54 -93.07 -98.31
10^9 -5.4 -12.05 -21.96 -60.02 -81.69 -98.97 -100
Ave. Percentage Reduction
 
 
Table 3.3.1.14:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 1 – 2 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.12 -0.49 -1.21 -1.96 -3.11 -4.22 -5.31
10^7 -0.163 -0.59 -1.4 -2.53 -3.4 -4.57 -6.29
10^8 -0.128 -0.6 -1.7 -2.4 -3.21 -4.4 -5.83
10^9 -0.078 -0.36 -0.6 -1.15 -1.8 -3.74 -6.33
Ave. Log Reduction
 
 
Table 3.3.1.15:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ofloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 4 - 8 μg/ml 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -6.25 -56.78 -85.28 -96.23 -99.78 -99.99 -100
10^7 -12.85 -59.88 -87.5 -99.58 -99.92 -100 -100
10^8 -9.15 -60.02 -67.11 -98.09 -99.02 -99.77 -100
10^9 -4.99 -50 -57.75 -78.52 -94.35 -99.91 -100
Ave. Percentage Reduction
 
 
Table 3.3.1.16:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ofloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 4 – 8 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.103 0.015 -0.105 -0.413 -0.9 -0.93 1.11
10^7 -0.03 0.01 -0.125 -0.98 -1.33 -0.88 0.82
10^8 0.013 0.025 -0.06 -0.26 -0.19 -0.57 -2.01
10^9 0.043 0.06 -0.11 -0.52 -0.85 -2.54 -4.84
Ave. Log Reduction
 
 
Table 3.3.1.17:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ciprofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 1 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 31.88 3.52 -7.05 -26.99 -41.93 -87.9 91.34
10^7 -6.44 2.63 -17.16 -84.57 -94.34 -37.25 85.62
10^8 3.04 5.8 -10.66 -34.43 -32.28 -70.7 -98.79
10^9 7.81 13.86 -21.37 -50.79 -83.67 -99.36 -100
Ave. Percentage Reduction
 
 
Table 3.3.1.18:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ciprofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 1 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.003 -0.28 -1.02 -1.33 -1.9 -3.55 -4.26
10^7 -0.14 -0.37 -1.25 -2.19 -2.78 -4.11 -5.16
10^8 -0.11 -0.26 -1.18 -1.77 -2.65 -3.73 -3.99
10^9 -0.08 -0.16 -0.47 -0.89 -0.98 -1.83 -4.68
Ave. Log Reduction
 
 
Table 3.3.1.19:  The average log10 reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ciprofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates  = 2 - 4 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 4.32 -43.06 -87.16 -97.36 -95.58 -99.95 -99.99
10^7 -25.72 -51.41 -88.69 -99.12 -99.82 -99.99 -100
10^8 -20.78 -41.25 -86.71 -96.71 -99.34 -99.95 -99.99
10^9 -16.52 -29.98 -62.72 -85.46 -88.6 -94.39 -100
Ave. Percentage Reduction
 
Table 3.3.1.20:  The average percentage reduction in viable cells of 4 clinical S. 
pneumoniae isolates exposed to ciprofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 2 – 4 μg/ml 
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Figure 3.3.1.1:   The Killing of S. pneumoniae ocular isolates (n = 4) at 106 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
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Figure 3.3.1.2:  The Killing of S. pneumoniae ocular isolates (n = 4) at 106 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration. 
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Figure 3.3.1.3:   The Killing of S. pneumoniae ocular isolates (n = 4) at 107 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
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Figure 3.3.1.4:   The Killing of S. pneumoniae ocular isolates (n = 4) at 107 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration. 
   
 
 
 
 
 
 
 
 67
-2.5
-2
-1.5
-1
-0.5
0
0.5
0.5 1 2 4 6 12 24
Hours
Lo
g 
R
ed
uc
tio
n Moxi
Gati
Levo
Cipro
Oflox
 
Figure 3.3.1.5:  The Killing of S. pneumoniae ocular isolates (n = 4) at 108 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
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Figure 3.3.1.6:  The Killing of S. pneumoniae ocular isolates (n = 4) at 108 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration.  
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Figure 3.3.1.7:  The Killing of S. pneumoniae ocular isolates (n = 4) at 109 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
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Figure 3.3.1.8:   The Killing of S. pneumoniae ocular isolates (n = 4) at 109 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration.  
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 At the MIC drug concentration for levofloxacin, there was a reduction in viable 
cells for the 106 and 107 cfu/ml inocula which peaked at 12 hours with a ≥ 90% (> 1.5 
log) reduction (Table 3.3.1.10, Fig. 3.3.1.1 – 3.3.1.3).  This was followed by re-growth 
at the 24 hour interval.  The 108 cfu/ml inoculum showed a 95% reduction of viable 
cells after 24 hours of drug exposure.  The 109 cfu/ml inoculum was reduced faster with 
a ≥ 99% reduction being achieved by 12 hours of drug exposure.  At the MPC the three 
lower inocula had viable cells reduced by ≥ 95% at 4 hours and 100% by 24 hours of 
drug exposure (Table 3.3.1.12).  The largest inoculum had a 92% reduction in viable 
cells by 6 hours and 100% by 24 hours.   
 With ofloxacin at the MIC drug concentration, significant viable cell reduction 
did not occur until 12 hours of drug exposure for the higher three inocula. (Table 
3.3.1.14, Fig. 3.3.1.1 – 3.3.1.8).  At 12 hours the 106 cfu/ml inoculum had a reduction in 
viable cells of 58%.  By 24 hours, however, all inocula had been reduced by at least 
95%.  At the MPC, the results were similar to the previous three fluoroquinolones 
(Table 3.3.1.16).  For the lower three inocula there was a significant reduction in viable 
cell by 4 hours (> 96%).  The 109 cfu/ml inoculum had a 94% viable cell reduction by 6 
hours and all inocula had a 100% reduction in viable cells after 24 hours of drug 
exposure. 
 With the exception of the 107 cfu/ml inoculum there was no reduction observed 
until 2 hours after exposure to ciprofloxacin at the MIC drug concentration (Table 
3.3.1.18, Fig. 3.3.1.1 – 3.3.1.8).  For the 106 cfu/ml inoculum, the reduction peaked at 
88% at the 12 hour interval.  Following that, there was re-growth.  The results for the 
107 cfu/ml inoculum were similar except the reduction in viable cells at 6 hours of drug 
exposure peaked at 94%.  The 108 cfu/ml inoculum reached a 32% reduction after 6 
hours of drug exposure and peaked with a 99% reduction of viable cells by 24 hours.  
At 6 hours the 109 cfu/ml inoculum had been reduced by 84%, and at 24 hours, 100%.  
At the MPC there was a viable cell reduction of ≥ 85% in all inocula by 4 hours (Table 
3.3.1.20).  By 24 hours all inocula had been reduced by ≥ 99.99%.                    
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3.3.2     H. influenzae 
 The kill curve results for moxifloxacin at the MIC are summarized in tables 
3.3.2.1 and 3.3.2.2 as well as Fig. 3.3.2.1 – 3.3.2.8.  At 106 cfu/ml there was growth at 
every time interval except 6 hours, when there was a 44% reduction in viable cells.  
Following 6 hours re-growth occurred.  The results at 107 cfu/ml fluctuated.  There was 
a slight reduction at the 0.5, 1 and 6 hour intervals and growth at the others.  At 108 
cfu/ml there was also sporadic growth and reduction.  However, following 24 hours of 
drug exposure there was a reduction in viable cells by 77%.  The 109 cfu/ml inoculum 
began with a substantial reduction of viable cells after 0.5 hours of drug exposure.  This 
was followed by re-growth until 4 hours.  The ensuing reduction of viable cells peaked 
at 99% after 24 hours.  The MPC results showed very quick and high levels of reduction 
for the lower three inocula (Table 3.3.2.4).  The 106 - 108 cfu/ml inocula attained a > 
92% reduction of viable cell after 2 hours of drug exposure.  The rate of reduction was 
slower at 109 cfu/ml.  It was not until 24 hours of drug exposure that a viable cell 
reduction of 99% was achieved.   
 The MIC kill results for gatifloxacin are similar to those of moxifloxacin (Table 
3.3.2.6, Fig 3.3.2.1 – 3.3.2.8).  The 106 and 107 cfu/ml inocula had a reduction in viable 
cells of 23 and 16% respectively for the first 2-hours of exposure to the drug.  Both of 
the higher inocula had bacterial reductions of ≥ 46% by 4 hours of drug exposure.  By 
24 hours, the 108 cfu/ml and 109 cfu/ml inocula had been reduced by 81% and 98% 
respectively.  At the MPC, the lower three of the four inocula experienced the quickest 
bacterial reductions (Table 3.3.2.8).  At 2 hours of drug exposure, the percentage 
reduction of viable cells ranged from 85 – 95% for 106, 107 and 108 cfu/ml.  By 24 
hours the reduction of viable cells reached ≥ 96%.  At 109 cfu/ml, a reduction of > 93% 
did not occur until after 12 hours of drug exposure. 
 With levofloxacin at the MIC drug concentration, re-growth was observed as 
early as 1 hour after drug exposure for the 106 and 107 cfu/ml inocula (Table 3.3.2.10, 
Fig. 3.3.2.1 – 3.3.2.3).  This was followed by a slight reduction at 4-6 hours and then 
more re-growth by 12 hours for the 106 cfu/ml inoculum.   At 108 cfu/ml there was a  
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.033 0.043 0.098 0.108 -0.43 0.8 1.23
10^7 -0.123 -0.08 -0.0075 -0.33 -0.1 0.24 0.48
10^8 -0.18 0.035 -0.05 0.085 0.063 -0.078 -0.038
10^9 -0.25 -0.32 -0.225 -0.31 -0.66 -1.1 -1.97
Ave. Log Reduction
 
Table 3.3.2.1:  The average log10 reduction in viable cells of 4 clinical H. influenzae 
isolates exposed to moxifloxacin at the Minimum Inhibition Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.004 – 0.031 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 7.49 7.8 37.35 90.06 -44.02 85.44 96.02
10^7 -9.55 -13.08 2.5 7.61 -44.02 38.9 68.3
10^8 -28.12 7.51 -5.67 29.64 26.28 28.95 -77.83
10^9 -40.61 -37.82 -27.35 -41.58 -65.37 -88.87 -98.79
Ave. Percentage Reduction
 
Table 3.3.2.2:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to moxifloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.004 – 0.031 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.53 -1.01 -2.02 -3.95 -4.17 -5.01 -6.47
10^7 -0.5 -1.08 -1.8 -3.3 -3.15 -4.51 -5.32
10^8 -0.22 -0.71 -1.24 -1.4 -1.34 -0.96 -1.6
10^9 -0.09 -0.088 -0.17 -0.2 -0.2 -1.34 -2.35
Ave. Log Reduction
 
Table 3.3.2.3:  The average log10 reduction in viable cells of 4 clinical H. influenzae 
isolates exposed to moxifloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.063 – 0.25 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -68.33 -88.44 -97.28 -99.93 -99.99 -100 -100
10^7 -64.65 -88.6 -95.04 -99.87 -99.77 -99.99 -100
10^8 -38.18 -72 -92.37 -94.09 -94.27 -86.78 -95.52
10^9 -15.18 -11.86 -30.49 -34.23 -36.65 -71.42 -99.52
Ave. Percentage Reduction
 
Table 3.3.2.4:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to moxifloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.063 – 0.25 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.003 0.045 -0.14 -0.54 -0.65 -0.43 0.53
10^7 0.068 -0.065 -0.15 -0.51 -0.44 -0.72 -0.26
10^8 -0.21 -0.19 -0.24 -0.48 -0.45 -0.5 -0.97
10^9 -0.083 -0.158 -0.31 -0.29 -0.25 -0.8 -1.74
Ave. Log Reduction
 
Table 3.3.2.5:  The average log10 reduction in viable cells of 4 clinical H. influenzae 
isolates exposed to gatifloxacin at the Minimum Inhibition Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.008 – 0.031 μg/ml 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -0.48 7.99 -23.48 -50.49 -43.12 -66.02 70.11
10^7 13.92 -10.16 -16.26 69 -65.63 -80.9 -37.99
10^8 -22.99 -18.21 -18.88 -52.28 -49.4 -42.02 -80.72
10^9 -14.21 -29.11 -48.02 -46.34 -43.55 -83.1 -98.18
Ave. Percentage Reduction
 
Table 3.3.2.6:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to gatifloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.008 – 0.031 μg/ml 
 
 
 
 
 
 
 
 
 76
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.33 -0.51 -1.37 -2.28 2.96 -4.19 -5.86
10^7 -0.19 -0.54 -0.98 -1.81 -2.05 -3.1 -1.27
10^8 -0.16 -0.51 -0.92 -1.22 -1.37 -2.2 -1.62
10^9 -0.063 -0.24 -0.19 -0.46 -0.48 -1.17 -2.2
Ave. Log Reduction
 
Table 3.3.2.7:  The average log10 reduction in viable cells of 4 clinical H. influenzae 
isolates exposed to gatifloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.031 – 0.125 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -48.43 -67.12 -95.31 -99.46 -99.76 -100 -100
10^7 -30.98 -67.37 -86.75 -97.77 -98.95 -99.9 -100
10^8 -29.47 -65.08 -84.6 -89.7 -91.37 -90.62 -96.32
10^9 -7.92 -36.7 -22.26 -65.23 -66.65 -93.19 -99.37
Ave. Percentage Reduction
 
Table 3.3.2.8:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to gatifloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.031 – 0.125 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.015 0.023 0.195 -0.043 -0.115 1.03 1.34
10^7 -0.03 0.03 0.15 0.83 0.6 0.24 0.34
10^8 -0.01 0.058 0.13 0.085 0.13 -0.19 -0.88
10^9 -0.16 -0.17 -0.19 -0.29 -0.43 -1.33 -2.43
Ave. Log Reduction
 
Table 3.3.2.9:  The average log10 reduction in viable cells of 4 clinical H. influenzae 
isolates exposed to levofloxacin at the Minimum Inhibition Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.004 – 0.016 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -3.52 3.79 37.35 -0.52 -22.02 90.1 95.98
10^7 -2.12 7.49 32.79 85.58 75.19 37.79 52.71
10^8 -1.41 13.86 30.22 17.86 30.22 33.8 -79.86
10^9 -14.93 -31.16 -17.86 -42.89 -82.52 -94.4 -99.14
Ave. Percentage Reduction
 
Table 3.3.2.10:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to levofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.004 – 0.016 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.71 -1.03 -1.15 -2.73 -3.51 -4.36 -5.69
10^7 -0.56 -1.01 -1.41 -2.17 -2.45 -3.34 -4.52
10^8 -0.31 -0.97 -1.31 -1.41 -1.36 -1.29 -1.49
10^9 0.24 -0.033 -0.19 -0.19 -0.21 -0.83 -2.07
Ave. Log Reduction
 
Table 3.3.2.11:  The average log10 reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to levofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates  = 0.125 μg/ml 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -74.05 -82.56 -93.69 -99.62 -99.96 -99.94 -100
10^7 -68.12 -83.53 -90.53 -98.89 -99.25 -99.91 -100
10^8 -37.79 -80.83 -88.87 -91.48 -90.83 -88.63 -95.86
10^9 38.2 13.69 -33.97 -35.05 -39 -83.15 -94.35
Ave. Percentage Reduction
 
Table 3.3.2.12:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to levofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.125 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.01 0.067 0.25 0.59 no data 2.46 1.54
10^7 -0.05 -0.055 0.12 1.26 0.52 0.5 0.38
10^8 -0.013 -0.083 -0.067 0.05 0.1 -0.065 -0.96
10^9 0.067 0.013 -0.02 -0.057 -0.093 -0.8 -2
Ave. Log Reduction
 
Table 3.3.2.13:  The average log10 reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ofloxacin at the Minimum Inhibitory Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.008 – 0.0.16 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 3.07 13.88 44.15 71 no data 99.66 97.03
10^7 -8.05 -11.16 32.1 93.41 69.77 69 52.23
10^8 -2.14 -15.38 -12.19 10.1 29.67 -9.7 -87.45
10^9 13.88 -2.14 -4.2 -11.66 -26.73 -76.66 -99.5
Ave. Percentage Reduction
 
Table 3.3.2.14:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ofloxacin at the Minimum Inhibitory Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.008 – 0.016 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.32 -0.84 -1.73 -2.74 -2.99 -3.9 -4.55
10^7 -0.25 -0.58 -1.44 -2.25 -2.55 -2.92 -3.94
10^8 -0.19 -0.62 -0.95 -0.91 -0.86 -0.64 -1.27
10^9 -0.015 0.01 -0.065 -0.14 -0.21 -1.11 -2.23
Ave. Log Reduction
 
Table 3.3.2.15:  The average log10 reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ofloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.125 – 0.25 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -46.24 -76.89 -93.96 -99.39 -99.66 -99.92 -99.95
10^7 -28.76 -68.01 -89.2 -98.19 -99.1 -99.77 -99.96
10^8 -30.61 -69.47 -83.7 -85.14 -82.78 -75.44 -93.77
10^9 9.84 10.09 -5.92 -12.06 -32.73 -91.04 -99.27
Ave. Percentage Reduction
 
Table 3.3.2.16:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ofloxacin at the Mutant Prevention Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.125 – 0.25 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 0.033 0.03 0.21 0.42 0.79 1.58 1.52
10^7 -0.028 0.065 0.21 0.47 0.75 0.82 0.56
10^8 -0.0025 0.065 0.205 0.288 0.255 0.158 -0.7
10^9 0.035 0.068 0.088 -0.018 -0.085 -0.78 -2.84
Ave. Log Reduction
 
Table 3.3.2.17:  The average log10 reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ciprofloxacin at the Minimum Inhibition 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.002 – 0.008 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 7.49 7.49 37.35 57.9 82.9 97.24 97
10^7 -3.95 13.88 37.35 60.37 81.3 85.64 71.63
10^8 1.44 13.88 37.34 38.3 37.9 97.03 -74.35
10^9 7.6 13.91 17.14 -2.9 -17.29 -83.34 -98.52
Ave. Percentage Reduction
 
Table 3.3.2.18:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ciprofloxacin at the Minimum Inhibitory 
Concentration.  
hr.  = hour 
MIC range of the 4 isolates = 0.002 – 0.008 μg/ml 
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Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr.
10^6 -0.38 -0.77 -1.4 -2.16 -2.4 -3.25 -4.67
10^7 -0.21 -0.77 -1.1 -1.81 -2.14 -3 -4.72
10^8 -0.22 -0.48 -0.62 -0.165 -0.23 -0.74 -1.01
10^9 0.073 -0.113 -0.16 -0.165 -0.23 -0.9 -2.01
Ave. Log Reduction
 
Table 3.3.2.19:  The average log10 reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ciprofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.063 – 0.125 μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
Inoculum (cfu/ml) 0.5 hr. 1 hr. 2 hr. 4 hr. 6 hr. 12 hr. 24 hr. 
10^6 -55.01 -71.29 -88.81 -97.06 -98.05 -99.71 -100
10^7 -36.4 -62.05 -84.16 -93.93 -96.92 -99.41 -100
10^8 -35.3 -53.48 -68.81 -69.84 -71.29 -71.7 -88.38
10^9 37.62 -16.24 -29.57 -29.99 -40.84 -85.49 -98.93
Ave. Percentage Reduction
 
Table 3.3.2.20:  The average percentage reduction in viable cells of 4 clinical H. 
influenzae isolates exposed to ciprofloxacin at the Mutant Prevention 
Concentration.  
hr.  = hour 
MPC range of the 4 isolates = 0.063 – 0.125 μg/ml 
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Figure 3.3.2.1:  The Killing of H. influenzae ocular isolates (n = 4) at 106 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. (data was not determined for ofloxacin at 6 hrs) 
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Figure 3.3.2.2:  The Killing of H. influenzae ocular isolates (n = 4) at 106 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration. 
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Figure 3.3.2.3:  The Killing of H. influenzae ocular isolates (n = 4) at 107 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
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Figure 3.3.2.4:  The Killing of H. influenzae ocular isolates (n = 4) at 107 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
concentration. 
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Figure 3.3.2.5:  The Killing of H. influenzae ocular isolates (n = 4) at 108 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
 
 
 
 
 
 
 
 
 
 88
-2.5
-2
-1.5
-1
-0.5
0
0.5 1 2 4 6 12 24
Hours
Lo
g 
re
du
ct
io
n Moxi
Gati
Levo
Cipro
Oflox
 
Figure 3.3.2.6:  The Killing of H. influenzae ocular isolates (n = 4) at 108 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration. 
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Figure 3.3.2.7:  The Killing of H. influenzae ocular isolates (n = 4) at 109 cfu/ml 
following exposure to each of the five fluoroquinolones at the Minimum Inhibitory 
drug concentration. 
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Figure 3.3.2.8:  The Killing of H. influenzae ocular isolates (n = 4) at 109 cfu/ml 
following exposure to each of the five fluoroquinolones at the Mutant Prevention 
drug concentration. 
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reduction of viable cells which amounted to 80% following 24 hours of drug exposure.  
The largest inoculum, however, was reduced by 83% at 6 hours and 99% by 24 hours.  
At the MPC concentration, a significant reduction occurred early on for the 106 – 108 
cfu/ml inocula (Table 3.3.2.12, Fig. 3.3.2.1 – 3.3.2.6).  As early as 1 hour after drug 
exposure, there was a reduction in viable cells of ≥ 80% for these lower inocula.  The 
equivalent reduction at 109 cfu/ml was not observed until after 12 hours of drug 
exposure.   
 Despite exposure to ofloxacin at the MIC drug concentration, significant growth 
was seen throughout the 24 hours of drug exposure at 106 cfu/ml (Table 3.3.2.14, Fig. 
3.3.2.1).  The 107 cfu/ml inoculum began with a slight reduction for the first two 
sampling intervals but began to re-grow after 2 hours.  There was no substantial 
reduction in viable cells for 108 cfu/ml until 24 hours of drug exposure when a 
reduction of 87% was noted.  At 109 cfu/ml, there was noticeable reduction in viable 
cells by 77%, which began at 12 hours following drug exposure and reached 99.5% by 
24 hours.  Following exposure to ofloxacin at the MPC, significant bacterial killing in 
the 106 – 108 cfu/ml inocula was evident after 2 hours of drug exposure.  By 12 hours 
the 109 cfu/ml inoculum had sustained a reduction in viable cells by 91% and by 24 
hours, all inocula had sustained a viable cell reduction of ≥ 93%. 
 As with the previous four fluoroquinolones at the MIC drug concentrations, the 
106 – 107 cfu/ml inocula proliferated throughout the 24 hours of exposure to 
ciprofloxacin (Table 3.3.2.18, Fig. 3.3.2.1 – 3.3.2.3).  No reduction in viable cells was 
observed at 108 cfu/ml until 24 hours of drug exposure.  The reduction of viable cells at 
109 cfu/ml began at 4 hours with a reduction of 3% and increased to 99% by 24 hours.  
The 106 and 107 cfu/ml inocula had a reduction of viable cells by ≥ 84% following 2 
hours at the MPC drug concentration (Table 3.3.2.20).  By 24 hours of drug exposure 
the 106 – 107 cfu/ml inocula had been reduced by 100%.  With the 108 and 109 cfu/ml 
inocula, bacterial reduction was 88% and 98% respectively by 24 hours of drug 
exposure.            
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4.0 Discussion 
 Sight is considered to be one of the most significant senses that humans possess.  
As a result, anything that threatens to compromise our visual integrity needs to be taken 
very seriously.  Bacterial infections pose such a threat.  While both Gram-positive and 
Gram-negative organisms are responsible for causing infections like conjunctivitis, 
keratitis and endophthalmitis, certain bacteria are more frequently recovered from 
ocular specimens than others.  In cases of conjunctivitis as many as 92% of recovered 
bacterial isolates are Gram-positive organisms such as S. pneumoniae and S. aureus (4).  
In pediatric conjunctivitis cases, H. influenzae and S. pneumoniae are most common 
with prevalence rates of 73% and 20% respectively (83).  With keratitis, Gram-positive 
bacteria are also the most prevalent pathogens with organisms like Staphylococcus 
epidermidis, S. aureus and S. pneumoniae being recovered 40%, 22% and 8% of the 
time respectively (29).  In endophthalmitis infections, the most prevalent pathogens are 
Gram-negative at 41.7%, with the most common one being  P. aeruginosa.  For 
endophthalmitis Gram-positives are present 37.6% of the time with S. epidermidis being 
the most likely organism of this group (84). 
Despite the availability of several antimicrobial classes for treatment of ocular 
infections, fluoroquinolones, due to their broad-spectrum activity, are especially 
effective (33).  However, like with any antimicrobial drugs, clinical use has resulted in 
the development of resistance (44).  This is exactly what has been observed with the 
older fluoroquinolones ciprofloxacin, ofloxacin and levofloxacin.  For example, 
Goldstein et al (85) showed that in S. aureus isolates from bacterial keratitis specimens 
resistance to ciprofloxacin and ofloxacin increased 6 to 7-fold between 1993 and 1997.  
Similar trends have been noted with S. pneumoniae.  A study done in the United States 
during 2000 assessed the susceptibility of 4009 S. pneumoniae isolates recovered from 
blood, respiratory, eye, ear and body fluid specimen.  Overall they found that only 71% 
of the isolates were sensitive to ciprofloxacin  (86). 
 In response, drug companies have worked to develop newer fluoroquinolones 
with improved in vitro Gram-positive activity.  This has resulted in two new agents 
being introduced, moxifloxacin licensed by Alcon, and gatifloxacin, currently licensed 
by Allergan.  Both drugs have a methoxy side-chain added at the R8 position.   In 
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addition, moxifloxacin has a bulky bicyclic ring attached at the R7 position while 
gatifloxacin has a methyl group on its piperazinyl ring (51).   These changes result in 
increased Gram-positive activity (lower MICs) as well as creating dual target activity.  
While the older fluoroquinolones interfere with either DNA gyrase or topoisomerase 
IV, moxifloxacin and gatifloxacin interfere with both  simultaneously (51).  This means 
that these new agents can potentially eradicate organisms that possess a mutation in the 
genes that encode for one of the two of the fluoroquinolone targets.  In other words, an 
infection caused by an organism that has become resistant to older fluoroquinolones 
can, theoretically, be treated with either gatifloxacin or moxifloxacin.  The newer 
fluoroquinolones have also been equipped with bulky side-chains making them less 
susceptible to bacterial efflux mechanisms such as NorA efflux membrane protein. 
 In the first part of my project, I attempted to compare the in vitro potency of 
fluoroquinolones’ towards bacteria pertinent to ocular infections.  Two of the most 
common Gram-positive organisms, S. pneumoniae and S. aureus, and two of the most 
common Gram-negative organisms, H. influenzae and P. aeruginosa, associated with 
ocular infections were used.  While the vast majority of susceptibility testing is done 
using the MIC method, it was thought that it was necessary to do MPC testing as well.  
While MIC testing is rapid and convenient (test results are available in 24 hours) it does 
not determine the susceptibility of a bacterial population that is most often present in an 
in vivo infection.  MIC tests employ a standardized test inoculum of 105 cfu/ml.  
However, this underestimates the true size of an in vivo bacterial load which can reach 
sizes of 1010 cfu in infections (81).  What is the significance of this underestimation?  
With the organisms used in this project, the spontaneous mutation frequency is 
approximately 10-7 to 10-9.  Therefore, if a person is infected with a bacterial load of 109 
cfu, that population is likely to have at least one organism with a first-step resistance 
mutation.  Because current dosing strategies have been determined using MIC 
susceptibility results, the prescribed dosage for an infection is based on a standard 
population of bacteria of 105 cfu in size;  a population not large enough for detecting 
first-step mutations that may arise.  Therefore the dosage approved may not be taking 
into consideration the presence of organisms with mutations.  As a result the dosage 
may be sufficient to kill the susceptible organisms within the population but may not be 
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high enough to kill the resistant ones, leading to selective enrichment of this resistant 
sub-population of bacteria.  This may be one mechanism by which global resistance is 
occurring to fluoroquinolones and perhaps other compounds as well.   
 While MPC testing may prove more accurate in assessing the true susceptibility 
of an organism, due to the large inoculum (109 cfu), there are some aspects to the test 
which keep it from being a realistic replacement for MIC testing.  The main hindrances 
lie in the conduction of the test itself.  MPC testing takes five to six days to complete 
and is more expensive and technically demanding.   
  Several observations were made based on the results of the susceptibility testing 
done in this project.  First, both the MIC and MPC results confirmed that, indeed, the 
new fluoroquinolones have better in vitro Gram-positive activity (lower MICs) against 
ocular pathogens.  Gatifloxacin and moxifloxacin were approximately four-times more 
active than the older fluoroquinolones for both S. pneumoniae and S. aureus.  Secondly, 
trends shown by the MIC results were reflected in the MPC results.  For instance, the 
increase in Gram-positive activity of the new fluoroquinolones against S. pneumoniae 
was between 4 and 8-fold as shown by the MIC results.  While the actual values were 
different for the MPC tests, the new fluoroquinolone values were shown to have the 
same-fold increase in Gram-positive activity (lower MPCs) as displayed by the MIC 
test.  Experiments done by Kowalski et al (47). show virtually identical MIC results for 
ocular S. pneumoniae isolates.  Their data showed MIC90 values for moxifloxacin and 
gatifloxacin at 0.19 and 0.25 µg/ml respectively, while the older fluoroquinolones had 
MIC90 values which were between 4 and 8-fold higher at 2 and 4 µg/ml for ofloxacin 
and ciprofloxacin respectively.  In 2001 Blondeau et al. (81) published MPC data on 
clinical S. pneumoniae isolates.  While their actual MPC90 values were slightly different 
than those determined in this thesis project, the increased in vitro potency of the new 
fluoroquinolones was observed.  Their data showed a 2 to 4-fold increase in the in vitro 
potency of gatifloxacin and moxifloxacin over levofloxacin.    
 The Gram-negative results were expected to be different than the Gram-positive 
results.  As the new fluoroquinolones were designed to be more active against Gram-
positives, I was not expecting to see a difference in in vitro Gram-negative activity.  
This is precisely what was observed.  As a whole, the MIC results for P. aeruginosa 
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were higher than for the other three organisms.  This is not a good sign considering P. 
aeruginosa is the leading cause of keratitis in contact lens associated keratitis (33).  The 
reason the Pseudomonas results seemed high, however, is because the population of 
organisms I tested contained three fluoroquinolone-resistant isolates based on recently 
published fluoroquinolone breakpoints presented by Morrissey et al. (87).    Because 
ciprofloxacin is the only fluoroquinolone, of the five tested, to be considered anti-
pseudomonal, the newer fluoroquinolones were expected to have less in vitro potency.  
Despite there being no increase in in vitro activity for the new fluoroquinolones, with 
respect to H. influenzae, the five fluoroquinolones were still very active against this 
organism.               
The results of the MPC testing from this project helped support the hypothesis 
that MIC results may be underestimating the actual drug concentration needed to 
eliminate susceptible and first-step resistant populations of bacteria which may be 
present in an in vivo infection.  The MPC results were consistently two to four-fold 
higher than the MIC results.  One additional point that needs to be emphasized is that 
current antimicrobial susceptibilities are based on PK/PD information from serum 
analysis (80).  However, in the case of superficial ocular infections like conjunctivitis 
and keratitis, drug concentrations greatly in excess of systemic limitations are 
achievable at the site of infection via topical application.  As a result, an organism that 
is considered resistant via traditional MIC testing, may be treatable if present as a 
superficial ocular pathogen. 
 While the first two experimental approaches examined the ability of five 
fluoroquinolones to inhibit the growth of typical ocular pathogens (MIC), and, inhibit 
the growth of first-step resistant mutants (MPC), the kill curve component was used to 
determine whether MIC or MPC drug concentrations were suitable for killing, S. 
pneumoniae and H. influenzae ocular isolates.  Previous kill studies done by Blondeau 
et al (88) showed a more rapid reduction in viable cells at the MPC than the MIC drug 
concentrations.  This same observation was made during my experiments.  With S. 
pneumoniae there was a rather dramatic difference both in the amount of time it took 
for a significant reduction of viable cells (99.9%) and the length of time the reduction 
lasted.  For example, at the MIC there was rarely a reduction of 99.9% of viable cells 
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before 12 hours, if at all.  In the cases where there was a significant reduction, it was 
followed by re-growth by 24 hours of drug exposure.  At the MPC drug concentration, 
there was a reduction by at least 99% for every drug at every inoculum size.  This effect 
was observable most often by 6 hours of drug exposure, and sometimes as early as 4 
hours of drug exposure with gatifloxacin and moxifloxacin.  At no time was any re-
growth observed at the MPC.   Ibrahim et al. (89) also conducted kill studies with S. 
pneumoniae.  While they did not utilize the MPC concept, they did conduct kill curves 
using concentrations at and above the MIC.  They too found that re-growth was a 
characteristic found only at the MIC drug concentration.  With drug concentrations in 
excess of the MIC, re-growth was not observed.    
 With H. influenzae there was even less killing at the MIC drug concentration 
than observed with S. pneumoniae clinical isolates.  There were only two instances 
where a 99% reduction of viable cells occurred.  The first was with levofloxacin at 109 
cfu/ml, and the second was with ofloxacin at 109 cfu/ml.  In both cases the 99% 
reduction did not occur until 24 hours following drug exposure.  Re-growth was evident 
consistently in the 106 – 107 cfu/ml inocula for each of the five fluoroquinolones.  While 
the rate of killing was faster at the MPC drug concentration, significant reductions were 
primarily observed in the lower two inocula and not until 6 – 12 hours.  Although 
significant reductions were not observed for the higher inocula, no re-growth occurred.  
Had there been a longer test period, the larger inocula may have reached a 99% 
reduction in viable cells following longer intervals of drug exposure.  Unfortunately, 
because the experimental method utilized to conduct these kill curves was relatively 
new I was unable, without further investigation, to explain why multiple growth 
fluctuations were observed throughout a couple of the kill tests.       
 Overall, the results from this project have shown that gatifloxacin and 
moxifloxacin do have significantly increased in vitro Gram-positive activity compared 
to the older compounds.  While in vitro Gram-negative activity seems to be well 
preserved amongst all the five fluoroquinolones tested, the results showed that perhaps 
P. aeruginosa, remains a problematic organism for the fluoroquinolone class as a 
whole.  However, to make such a generalization, one would need to conduct a multi-
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center study with hundreds of P. aeruginosa isolates using the most commonly 
prescribed fluoroquinolones and compare in vitro results to clinical outcome.  
 It was also shown that the MPC test more accurately represents the drug 
concentration needed to eradicate the type bacterial populations present in an in vivo 
infection.  This means that the MPC test takes into consideration the actual size of the 
bacterial load which may be present in the average infection.  As well, it takes into 
account the presence of first-step mutants which may be present in any bacterial 
inoculum which is greater than 106 cfu.                                                        
 
5.0     Future Considerations 
 Unfortunately, due to the time restraints of this project, it was not possible to 
examine all the aspects of drug performance within an ocular setting.  While I was able 
to compare the in vitro potency of gatifloxacin and moxifloxacin to older 
fluoroquinolones like ciprofloxacin, ofloxacin and levofloxacin, there are additional 
questions that need to be investigated.  For example, an animal model could be used in 
order to determine the ability of the new fluoroquinolones to maintain therapeutic 
concentrations in the tear film.  As well, the five fluoroquinolones need to be examined 
for their ability to penetrate the cornea following standardized topical administration.  If 
sufficient corneal penetration is achieved, we need to see how long it takes to reach 
therapeutic concentrations in the aqueous and vitreous humors.   
 With regards to the kill curve experiments, further investigation needs to be 
done to find out what is actually going on in each test tube.  High Performance Liquid 
Chromatography (HPLC) needs to be used to determine how quickly the nutrients in the 
broth as well as the drugs, are being used up over the 24 hour test period.  With this 
instrument you can measure the amount of drug or nutrient in the sample.  This is 
important because in order to test the true pharmacodynamics, there has to be sufficient 
nutrient and drug concentrations present throughout the entire test period.     
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7.0     APPENDIX A 
 7.1     Solutions and Media 
  Hemin 
Dissolve 0.05 g in 1 ml of 1N NaOH.  Add to 10 ml of sterile deionozed 
water.  Final stock concentration is 5 mg/ml. 
 
  HTM (agar/broth) 
Add 38 g of Mueller Hinton II agar (for broth add 38 g MHB instead), 5 
g of yeast extract and 3 ml of 5 mg/ml Hemin to 1 L of distilled water.  
Autoclave and when cooled to 50°C add 3 ml of 15 μg/ml NAD. 
 
  NAD 
Dissolve 0.05 gm in 10 ml of distilled water.  Sterilize by filtering 
through a 0.45 millipore filter. 
   
  MHB 
  Add 21 g to 1 L of distilled water and then autoclave 
 
  Skim Milk 
  Add 200 g to 1 L of distilled water and then autoclave.   
 
  THB 
  Add 30 g to 1 L of distilled water and then autoclave. 
 
  TSA 
  Add 40 g to 1 L of distilled water and then autoclave. 
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8.0     APENDIX B 
 8.1     Preparation of Antimicrobial Agents 
  Ciprofloxacin 
Dissolve 0.1 g into 10 ml of sterile distilled water.  At 84.6% purity the 
final concentration is 8460 μg/ml. 
 
  Gatifloxacin 
Dissolve 0.035 g into 10 ml of sterile distilled water.  At 93.3% purity, 
the final concentration is 3265.5 μg/ml. 
 
  Levofloxacin 
This agent is available in an injectable form at 25 mg/ml.  Dilute to 
desire concentration.   
 
  Moxifloxacin 
Add 0.02 g to 10 ml of sterile distilled water.  At 87.8% purity the final 
concentration is 1756 μg/ml. 
 
  Ofloxacin 
Add 0.05 g to 10 ml of sterile distilled water.  Add 4 drops of NaOH to 
help dissolve the powder.  The final concentration is 5000 μg/ml.   
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9.0     APPENDIX C 
 10.1     Suppliers 
10.1.1     Media 
 
Chocolate Agar Plates  PML Microbiologicals, Winnipeg, MB 
Haemophilus Test Media  PML Microbiologicals, Winnipeg, MB 
Mueller Hinton Broth (MHB)  Becton, Dickinson and Co., Sparks, MD 
Todd Hewitt Broth (THB)  Becton, Dickinson and Co., Sparks, MD 
Tryptic Soy Agar (TSA)   Becton, Dickinson and Co., Sparks, MD 
5% Sheep Blood   Oxoid 
Yeast Extract    Becton, Dickinson and Co., Sparks, MD 
9.1.1     Antimicrobial Agents 
 
Ciprofloxacin    Bayer, West Haven, CT 
 Gatifloxacin    Allergan Inc., Irvine, CA 
 Levofloxacin    Janssen-Ortho Inc., North York, ON 
 Moxifloxacin    Bayer, Mt. Prospect, IL 
 Ofloxacin    Allergan Inc., Irvine, CA 
9.1.2     Reagents and Chemicals 
 
95% Alcohol    Commercial Alcohols Inc., Brampton, ON 
Glycerol    BDH Inc., Toronto, ON 
Hemin     SIGMA 
β-Nicotinamide Adenine Dinucleotide  SIGMA, 
Saline      Baxter, Deerfield, IL 
Skim Milk    Becton, Dickenson and Co., Sparks, MD 
Sodium Hydroxide (NaOH)   BDH Inc., Toronto, ON 
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9.1.3     Disposable Labware 
 
200 μl Pipette Tips   VWR International, Edmonton, AB 
Corning Cryovials    Corning Inc., Corning, NY 
Cuvettes    Fisher Scientific, USA 
Glass Tubes    Fisher Scientific, USA 
Latex Gloves    Fisher Scientific, USA 
McFarland Tubes   Fisher Scientific, USA 
Microtitre Plates   Sarstedt, Newton, NC 
Pasteur Pipettes   Fisher Scientific, USA 
Sterile Plastic Petri Plates  Fisher Scientific, USA 
Swabs     Fisher Scientific, USA 
Wooden Applicator Sticks  Puritan, Guilford, Maine 
 
9.1.4      Equipment 
 
20 μl, 200 μl and 1 ml Pipettors Gilson Company, Inc., Lewis Cener, OH 
-70°C Freezer     Forma Scientific Inc., Marjetta, OH 
Avanti J-E Centrifuge   Beckman Coulter, Palo Alto, CA 
Colorimeter    Hach Company, Loveland, CO 
Hot Plate/Stirrer-Model 300T  Fisher, Scientific, USA 
pH Meter    Corning Inc., Corning, NY 
Oxygen Incubator   Hotpack Corp., Philadelphia, PA 
Shaking Water Bath   Mandel Scientific Co., Guelph, ON 
Spectrophotometer   Pharmacia, Cambridge, England 
Vortex (Mini-shaker Model 58) Fisher Scientific, USA 
Weigh Scale – Mettler PC440 DeltaRange, Zurich, Switzerland 
 
